Nursing

Thesis and Dissertations

2021-06

Time to First Optimal Glycemic Control and its Predictors Among Type 1 Diabetic Children<15 Years In Bahir Dar City Public Referral Hospitals, North West, Ethiopia, 2021

Fentahun, Meseret

http://ir.bdu.edu.et/handle/123456789/13775 Downloaded from DSpace Repository, DSpace Institution's institutional repository



BAHIR DAR UNIVERSITY

COLLEGE OF MEDICINE AND HEALTH SCIENCES

SCHOOL OF HEALTH SCIENCES

DEPARTMENT OF PEDIATRICS AND CHILD HEALTH NURSING

TIME TO FIRST OPTIMAL GLYCEMIC CONTROL AND ITS PREDICTORS AMONG TYPE 1 DIABETIC CHILDREN<15 YEARS IN BAHIR DAR CITY PUBLIC REFERRAL HOSPITALS, NORTH WEST, ETHIOPIA, 2021

BY: FENTAHUN MESERET (BScN)

BAHIR DAR, ETHIOPIA, JUNE, 2021

BAHIR DAR UNIVERSITY COLLEGE OF MEDICINE AND HEALTH SCIENCES SCHOOL OF HEALTH SCIENCES DEPARTMENT OF PEDIATRICS AND CHILD HEALTH NURSING TIME TO FIRST OPTIMAL GLYCEMIC CONTROL AND ITS PREDICTORS AMONG TYPE 1 DIABETIC CHILDREN<15 YEARS IN BAHIR DAR CITY PUBLIC REFERRAL HOSPITALS, NORTH WEST, ETHIOPIA, 2021

THESIS SUBMITTED TO BAHIR DAR UNIVERSITY COLLEGE OF MEDICINE AND HEALTH SCIENCE, DEPARTMENT OF NURSING FOR PARTIAL FULFILMENT OF M.SC. DEGREE IN PEDIATRICS AND CHILD HEALTH NURSING

BY: FENTAHUN MESERET (B.Sc.)

EMAIL:mesie1055@gmail.com

PHONE: +251920517132

ADVISORS: 1.AMARE BELACHEW (M.SC., ASSISTANT PROFESSOR)

EMAIL: dagnewamare@gmail.com

2. GETASEW TESFA (M.SC., ASSISTANT PROFESSOR)

EMAIL: getasewtesfa@gmail.com

JULY, 2021

BAHIR DAR, ETHIOPIA

© 2021[Fentahun Meseret]

DECLARATION

This is to certify that the thesis entitled "Time to first optimal glycemic control among type one diabetic children in Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021", submitted in partial fulfillment of the requirements for master of degree in pediatrics and child health nursing,in Bahir Dar University, is a record of original work carried out by me and has never been submitted to this or any other institution to get any other degree or certificates. The assistance and help I received during the course of this investigation have been duly acknowledged.

Fentahun Meseret6/22/2021Bahir Dar

Date

Name of the candidate

Place

ADVISOR'S APPROVAL FORM

BAHIR DAR UNIVERSITY COLLEGE OF MEDICINE AND HEALTH SCIENCES SCHOOL OF HEALTH SCIENCES DEPARTMENT OF PEDIATRICS AND CHILD HEALTH NURSING

Approval of thesis for defense

I hereby certify that I have supervised, read, and evaluated this thesis entitled with "Time to first optimal glycemic control among type one diabetic children in Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021" by <u>Fentahun Meseret</u> prepared under my guidance. I recommend the thesis/dissertation be submitted for defense.

Advisor's name

Signature

Date

1. Mr.Amare Belachew (Ass't prof.)_____

2. Mr.Getasew Tesfa (Ass't Prof.) _____

EXAMINER'S APPROVAL FORM

BAHIR DAR UNIVERSITY

COLLEGE OF MEDICINE AND HEALTH SCIENCES

SCHOOL OF HEALTH SCIENCES

DEPARTMENT OF PEDIATRICS AND CHILD HEALTH NURSING

Approval of thesis for defense

We hereby certify that we have examined this thesis entitled "Time to first optimal glycemic control among type one diabetic children in Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021"by Fentahun Meseret We recommend and approve the thesis a degree of "MSc in pediatrics and child health nursing"

Board of Examiners

Mr. Zebenay (Ass't prof.@SPMMC		
External examiner's name	Signature	Date
Miss. Aden Amsalu (Ass't prof.)		
Internal examiner's name	Signature	Date
Mr. Minichil Birhanu (Ass't prof.)		
Chair person's name	Signature	Date

ACKNOWLEDGEMENT

First, I would like to express my Acknowledgement to Bahir Dar and Haramaya University College of medicine and health science for giving to me such golden opportunity to pursue my M.Sc. education in nursing and to enroll on this research preparation.

Secondly, I would like to express my deepest gratitude and great full thanks to my Advisors, Amare Belachew (M.Sc., Assistant professor) and Getasew Tesfa (M.Sc., Assistant professor) for their constructive comments starting from proposal writing to the final thesis work.

Finally, I would like to extend my acknowledgment to Bahir Dar university library, Felege Hiwot and Tibebe Ghion specialized hospital staffs for their cooperation when I was in need of information related to this research writing.

ABSTRACT

Background: Recognizing the level of glycemic control of a client is an important predictor of the development of complication and risk of death from diabetes. However, the other most important predictor which is the time that the patient stayed in that poor glycemic level before reaching optimal glycemic control has not been studied so far.

Objective: The aim of this study was to estimate time to first optimal glycemic control and identify predictors among type 1 diabetic children<15 years in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021

Methods: Retrospective cohort study was conducted at Bahir Dar city public referral hospitals among randomly selected sample of 385 patients with type 1 diabetes who were on follow up from January1, 2016 to February30, 2021.Data were collected by using data abstraction tool and then entered into Epidata version 3.1 and exported into STATA 14.2 statistical software. Descriptive statistics, Kaplan Meier plots and median survival times, Log-rank test and Cox-proportional hazard regression were used for analysis. After performing Cox-proportional hazard regression, model goodness-of-fit and assumptions were checked. Finally, association between independent variables and time to first optimal glycemic control in months were assessed using multivariable Cox Proportional Hazard model and Variables with p-value < 0.05 were considered as statistically significant.

Result: Median survival time to first optimal glycemic control among type 1 diabetic client was 8 months (95%CI: 6.9-8.9).First optimal glycemic achievement rate was 8.2(95%CI: 7.2-9.2) per 100 person/month observation. Factors that affect time to first optimal glycemic control were age (AHR=0.32;95%CI=0.19-0.55),weight(AHR=0.96;95%CI=0.94-0.99),primary care giver(AHR=2.09;95%CI=1.39-3.13), insulin dose (AHR=1.05;95%CI=1.03-1.08),duration of diabetes (AHR=0.64;95%CI=0.44-0.94), adherence (AHR=9.72;95%CI=6.09-15.51),carbohydrate counting(AHR=2.43;95%CI=1.12-5.26),and comorbidity (AHR=0.72;95%CI=0.53-0.98).

Conclusion and Recommendation: Median survival time to first optimal glycemic control among type 1 diabetic clients were too long.which, indicates that clients are being unprotected for complication. Hence, diabetic care should be strengthen to shorten time to first optimal glycemic control.

Key words: type 1 diabetes mellitus, First optimal glycemic control, Time, children, Ethiopia

DECLARATION	i
ADVISOR'S APPROVAL FORM	ii
EXAMINER'S APPROVAL FORM	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
LIST OF FIGURES	ix
LIST OF TABLES	x
LIST OF ANNEXES	xi
LIST OF ACRONYMS AND ABBREVIATIONS	xii
1. INTRODUCTION	1
1.1. Background	1
1.2. Statement of the problem	
1.3. Significance of the study	5
1.4. Objective	5
1.4.1. General objective	5
1.4.2. Specific objectives	5
2. LITERATURE REVIEW	6
2.1. Incidence of first glycemic control among type 1 diabetic children	6
2.2. Predictors associated with glycemic control among type 1 diabetic children	7
2.2.1. Socio demographic predictors of glycemic control	7
2.2.2. Comorbidity associated predictors of glycemic control	
2.2.3. Person and clinical predictors of glycemic control	9
2.3. Conceptual frame work	
3. METHODS AND MATERIALS	
3.1. Study area and period	
3.2. Study design	
3.3. Source, study population and study unit	
3.3.1. Source population	
3.3.2. Study population	14

PAGES

3.3.3. Study unit	. 14
3.4. Inclusion and exclusion criteria	. 14
3.4.1. Inclusion criteria	. 14
3.4.2. Exclusion criteria	. 14
3.5. Sample size determination	. 14
3.6. Sampling technique and procedure	. 15
3.7. Study variables	. 16
3.7.1.Dependent variables	. 16
3.7.2. Independent variables	. 16
3.8. Operational definitions	. 16
3.9. Data collection procedure	. 17
3.10. Data quality assurance	. 17
3.11. Data processing and statistical analysis	. 17
3.12. Ethical considerations	. 18
3.13. Dissemination of the result	. 18
4.RESULT	. 19
4.1. Socio demographic characteristics	. 19
4.2. Median survival time to first optimal glycemic control	. 20
4.3. Incidence rate of optimal glycemic achievement rate	. 20
4.4. Diabetes related variables	. 20
4.5. Comorbidity related variables	. 22
4.6. Survival estimates for time to first optimal glycemic control	. 23
4.7. Comparison of survival experience	. 25
5.DISCUSSION	. 33
6.STRENGTH AND LIMITATION OF THE STUDY	. 36
6.1 Strength of the study	. 36
6.2. Limitation of the study	. 36
7. CONCLUSION AND RECOMMENDATION	. 37
7.1. Conclusion	. 37
7.2. Recommendation	. 37
REFERENCES	. 39
ANNEXES	. 48

LIST OF FIGURES

Figure 1:Time to first optimal glycemic control concept map among type 1 diabetic children in Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021------12

Figure 2: Kaplan-meier survival estimate of time to first optimal glycemic control among type one diabetic children having follow up at Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021-----25 Figure 3: Kaplan Meier survival estimate for time to optimal glycemic control among type one diabetic children with history of comorbidity in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021-----25

Figure 4: survival and hazard function of adherence by time, among T1DM children in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021-----29

Figure 5: Model goodness of fit by cox Snell residual among type 1 DM children in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021------30

Figure 6: log of minus the Log of survival function by comorbidity and carbohydrate count for time to first optimal glycemic control among type 1 diabetic children in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021------33

LIST OF TABLES

Table 1:Sample size calculation to estimate time to first optimal glycemic control among type one diabetic children in Bahir Dar city public referral hospitals, North West, Ethiopia, 2021------15

Table 2: Sociodemographic and institution related variable with censuring and event status among type 1 diabetic clients in Bahir Dar city public referral hospitals, Northwest Ethiopia, 2021(n=385)

Table 3: Diabetes related variable with censuring and event status among type 1 diabetic clients, in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385) ------22

Table 4: Comorbid illness related variable with censuring and event status among type 1 diabetic clients in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385) ------23

Table 5: Comparisons of optimal glycemic control among type 1 DM clients in Bahir Dar citypublic referral hospitals, Northwest, Ethiopia, 2021(n=385)------27

Table 6: Test of proportional-hazards assumption by schoen field residual test (Global test) among type 1DM clients in Bahir Dar city public referral hospitals, Northwest, Ethiopia,2021(n=385) ---

------31

Table 7: Results for the final cox regression hazard model among type 1DM clients in Bahir Dar city public referral hospitals, Northwest, Ethiopia,2021(n=385) -------34

LIST OF ANNEXES

Annex I: Information sheet for staffs working on patient's card room at Bair Dar city public referral hospitals, Northwest, Ethiopia ,2021-----48

Annex II: check list to collect relevant information to measure association between time and optimal glycemic control among diabetic children in Bahir Dar city referral hospitals, Northwest, Ethiopia, 2021------53

Annex III: Life table to estimate cumulative survival probability after diagnosis among type 1 diabetic clients, in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021-----51

Annex IV: Test of interaction by Multicollinearity among type 1 diabetic clients, in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021-----56

LIST OF ACRONYMS AND ABBREVIATIONS

ADA	American Diabetic Association
BGM	Blood Glucose Monitoring
CGM	Continuous Glucose Monitoring
DCCT	Diabetes Control and Complication Trial
DCT	Diabetic Care Team
DM	Diabetes Mellitus
EDIC	Epidemiology of Diabetes Interventions and Complications
FBS	Fasting Blood Glucose
HbA1c	Glycated Hemoglobin A1 C
IDF	International Diabetic Federation
ISPAD	International Society of Pediatrics and Adolescent Diabetes
NCDs	Non Communicable Diseases
NCDs SMBG	Non Communicable Diseases Self-Monitoring of Blood Glucose
SMBG	Self-Monitoring of Blood Glucose
SMBG SSA	Self-Monitoring of Blood Glucose Sub Saharan Africa
SMBG SSA T1DM	Self-Monitoring of Blood Glucose Sub Saharan Africa Type 1 Diabetes Mellitus

1. INTRODUCTION

1.1. Background

Glycemic control is a level of glucose in diabetic clients and it is a cornerstone of diabetes mellitus(DM) management, in which, it requires extensive attention to balance insulin with diet and exercise to reduce the risk of diabetic complication(1).DM is a serious, chronic and progressive disease that occurs either when the pancreas does not produce enough insulin or the body can not properly use the insulin it produces(1).There are three classification of diabetes mellitus commonly accepted by different scholars(1,2).These are: type one diabetes mellitus(T1DM) ,type two diabetes mellitus(T2DM) and gestational diabetes(3).According to American diabetic association(ADA) type one is the commonest type in pediatrics age categories(2).

Type 1 diabetes also known as insulin dependent, juvenile or child hood onset DM which is characterized by deficient insulin production in the body(1). It encompasses a group of metabolic disease causing in hyperglycemia(2). Juvenile diabetes is currently not preventable but we can control and prevent its complication. Otherwise, uncontrolled diabetes over time may lead to a serious damage to the heart, blood vessels, eyes, kidneys and nerves(1-5).

A patient indicating any of the following can diagnosed as having diabetes based on ADA and international society of pediatrics and adolescent diabetes(ISPAD) recommendation: fasting blood glucose(FBG) \geq 126 mg/dL (11.1mmol/L), poly symptoms of diabetes plus random blood sugar \geq 200 mg/ (7 mmol/L) or 2 hour plasma glucose during glucose tolerance test. \geq 200 mg/ (7 mmol/L) and glycosylated/glycated (Hb A1) \geq 6.5 %.(2,6).

Gglycemic control followed by the diagnosis was reflected by optimal and poor metabolic control as mean HbA1c <7.5% and >7.5% respectively and /or average FBG level between 80-150mg/dl and either < 80 or >150 mg/dl respectively(6- 8,80) and HbA1c can be calculated from the following formula, if HBA1c is not consistently available for some of the clients; estimated average glucose level in (mg/dl)=28.7*HbA1c-46.7(8).

In general, there have been significantly numerous advances in the quality of T1DM care including more physiologic insulin, continuous subcutaneous insulin pump therapy, and sophisticated blood

glucose monitoring and newer educational strategy[7].But, glycemic control leftovers poor and suboptimal for many of the patients with T1DM (7,8).

Clients with equivalent level of poor glycemic control can have different prognosis because of the difference in the time the patient retain on that poor glycemic level. Meaning the hazard of complication and death occurrence rises as the client remain longer in that poor glycemic state(3).

Therefore, if efforts are not made to recognize the contributing factors for optimal glycemic control with possible time frame, the number of children affected will preserve growing and this in turn lead to an emotional and economical burden on both the clients and the families at large(6). And it will also disturb the sustainability of our health care system which is still over burdened with communicable diseases.

1.2. Statement of the problem

Diabetes mellitus pandemic have become one of the largest global health emergencies among non-communicable disease in this century(3). In many countries, over 500 000 children < 15 years old are diagnosed with T1DM(4,6-8)with an average incidence of around 3% to 4% per year worldwide(6,7). This increment is also noted more alarmingly in other developing countries(9,10-14).

Although there are a lots of advanced management of T1DM,more than 70% of them were unable to maintain their glycaemia(10,11). More over noncompliance rate escalating 50% that highlights the need for focusing on timely optimal glycemic control during management(10). Many children had also suffered from T1DM which is associated with high morbidity, mortality rate and most of the time the poor has been highly affecting by this disease (9,15,16). Both In developed and developing nations the prognosis of children with T1DM is poor (14). As a result, optimal glycemic control were oscillating from 2.6% to 39.1%(11,15,17). Many are not detected and those diagnosed have dramatically reduced their life expectancy by one year,(17-19)and poor glycemic control was much higher among type one patients(82.9%) as compared with type two diabetics(57.7%)(14, 20, 21).

A varieties of factors that predict glucose control in children with T1DM have documented (7,18-22). High proportion of patients with uncontrolled glycemic level were due to sociodemographic factors, concomitant disease, personal and other clinical factors (16,17,23); health care system with limited resources, lack of trained health personnel and in ability of the patient or family to use and afford treatment expenditures (10,24).

Uncontrolled glycemic situation results complication which can hurt many parts of the body including growth failure later in time(3,22–24). As a result, both acute and chronic complications were reported in different studies(24). Adverse effects like lipodystrophy is one of the clinical complication which may occur related to insulin injection and leads to insulin absorption problems, which ultimately can hinder first optimal glycemic control achievement in short period of time(25,26). The most common complication prior in three months were hypoglycemia which accounts 21-42% followed by 31.5%-39% diabetic keto acidosis(DKA), 10.5%-32.9% nephropathy, 13.6% neuropathy, 10.5% convulsion, 10.3% retinopathy and 5.2% includes the

cumulative of hypokalemia, cerebral edema and coma (27–29). Majority of diabetes morbidity and mortality rate were related to this complication(30-32).Sustained abnormal blood sugar fluctuation for periods of greater than two months can also contribute to high burden of the disease, hospitalization and negative consequences of disease out comes(30,32).

Similarly, study in Ethiopia highlights the difficulty of achieving glycemic control early in time. As a result, early occurrence of both retinopathy and maculopathy among diabetic children were reported(13). Another study In Ethiopia specifically in Gojjam, also indicates 58.5% DKA among 354 T1DM children with the incidence rate of 2.27/100 children/month of observation.(31).

However, strict glycemic control minimizes the incidence and progression of such possible complication(14–17). The Diabetes Control and Complication Trial (DCCT) and the follow-up study Epidemiology of Diabetes Interventions and Complications (EDIC) shows that, good glycemic control with in short duration after onset the disease delays the development of both acute and chronic complication in T1DM patients by 35-76% (9). Novel treatment are emerging to manage T1DM with the ultimate goal being to achieve glycemic control, limit weight gain, reduce comorbidities and improve quality of life(7). T1DM treatment is based on frequent monitoring of blood glucose and administration of insulin, in line with their meal and exercise(33-35). It was recommended that T1DM children should check their blood glucose at least four times a day(6). And which expected to bring 26.2% satisfactory glycemic control level (7,35). People with diabetes can live longer and have a healthy life if their diabetes is become aware of early and well-managed by multidisciplinary approach by highly specialized team members with the allocation of accessible resources(10,36,37). Being updated about the recent diabetes care can also help in improving first glycemic control (15,38).

In Ethiopia a little studies were conducted to recognize level of glycemic control among type one diabetic children(16). Though recognizing the level of glycemic control is an important predictor of the development of complication and risk of death from diabetes, the other most important predictor which is the time, in which, the patient stayed on that poor glycemic level before reaching optimal glycemic control has not studied so far.

Therefore, this study was aimed to estimate time to first optimal glycemic control among type 1 diabetic children in Bahir Dar city public referral hospitals, Northwest, Ethiopia.

1.3. Significance of the study

This study can bring out positive implications for clinical care, health service management and researches with in an area of diabetic specialization.

Clinically the health care worker can identify predictors associated with time to first optimal glycemic control among type one diabetic children at clinical setup.

The findings from this study could create valuable data for the healthcare system potentially by helping policy makers, health care managers and other responsible persons such as families and other stockholders of the registry to adjust their approaches

Researcher can also motivated to conduct further researches in this area by taking this study as preliminary findings.

1.4. Objective

1.4.1. General objective

To assess time to first optimal glycemic control and identify predictors among type 1 diabetic children<15 years in Bahir Dar city public referral hospitals, Northwest Ethiopia, 2021

1.4.2. Specific objectives

- 1. To estimate time to first optimal glycemic control among type 1 diabetic children<15 years
- 2. To identify predicting factors among type 1 diabetic children<15 years
- 3. To determine level of glycemic control

2. LITERATURE REVIEW

2.1. Incidence of first glycemic control among type 1 diabetic children

Incidence and prevalence of optimal glycemic control among T1DM children were varied by age, gender, geographic location and other clinical condition(28). A prospective study followed for 18-24 months among 150 children in 2015 in California revealed that, only one third of them were meet treatment targets(39) and 20.9%-39.1% of optimal glycemic control were reported in recent study(2019) among Asian diabetic children(36).

A study conducted for six month in Kenya indicated that, the overall optimal glycemic control was 28% (40)which is reasonably low than expected. A 31 year trend retrospective analysis of data on diabetes admission ,morbidity and mortality rates at tertiary referral hospitals in Ghana recognized that, females were predominantly admitted with T1DM in the ratio of 1.3:1.0 (41)and inpatient diabetes admission rate increased from 2.36 to 14.94 per 1000 with the average mortality rate of 18.5%(41). A study in Tanzania in 2016 with seventy five participants also discovered that, children less than 10 years(9.8%) were found to have better glycemic control compared to 10-14 and >14 years old(11.4-11.5%)(32). Another recent study(2019) in Tanzania among 150 participants revealed that, only four(2.6%) of them had optimal glycemic control (HbA1c<7.5%) (26). A study from 300 children in Nigeria also reported that, both hypoglycemia and hyperglycemia (20.7% and 39%)respectively covers the highest incidence of emergency admitted cases related to poor glycemic control; which significantly associated with mortality(42). Other analogous study in Tanzania published in 2020 also showed that, 32.9% nephropathy, 10.3% retinopathy and 13.6% neuropathy were documented(27). Almost similar finding was reported in in Malawi with high incidence of poor glycemic control among the study population(43).

A systematic review which was published on august 27/2019 indicated that, poor glycemic control among all age categories of diabetic patients in Ethiopia is 64.72%-66.2% based on HbA1c and FBG measurements respectively(17). Another study conducted in 2016 at Addis Ababa among diabetic children also showed that, 52.3% of them had poor glycemic control from a total of 86 clients with 4.7% retinopathy(13).

A retrospective cohort study in Gojjam Ethiopia also indicates 58.5% of DKA among 354 T1DM children with the incidence rate of 2.27/100 children/month of observation.(31).

2.2. Predictors associated with glycemic control among type 1 diabetic children

2.2.1. Socio demographic predictors of glycemic control

Studies indicated that, discrepancies of glycemic control among diabetic children by their age, gender and geographic location were still not as such certain (28). A prospective study in California University and Thailand have proved that, demographic factors may call for proactive efforts to prevent deterioration, while family engagement could be used as an opportunities for clinical intervention to promote better diabetes management and control in older children(44,45). Glycemic control level with in the age pattern among Bulgarian children in 2017 showed that, teenagers had higher HbA1c levels as compared from the other age groups. 8.8%±1.87% (46).

A recent study (2019) in Iraq indicated that, glycemic control was significantly affected by the children's age, while it had no significant association with other demographic factors including sex, parent education level and family economic status(47).whereas a study conducted in Iran recognized that, being female sex is a risk factor on glycemic control and type one diabetes associated complication.(48).A retrospective study in Taiwan similarly reported that, glycemic control among type 1 diabetes had an association with in both sex, age groups and in residents particularly more in urban area (49).A recent retrospective cohort study in middle east Jordan published on July 2019 also revealed that, poor metabolic control was associated with age and absence of direct mother care(50).Another study in Saudi Arabia also recognized that, fathers educational level and employment status had a positive relation with glycemic control among type 1 diabetic children than mothers education and employment status(51).

As a child with diabetes develops, he/she under goes a varieties of physical, psychological, and life style changes(24). This Changes together with his /her interaction to the environment, tends to influence the glycemic control with long or short period of time in these children(12,24). Multi-disciplinary health care team(DCT) with expertise in supporting, handling and treating a child and family is required when they face with varies challenges(10,19, 40,52). Two contemporary longitudinal population based pediatrics cohort study of T1DM in boys and girls among injection therapy/pump regimen groups revealed, as there was concurrent improvements in HbA1c and /or average FBG level and decreasing sever hypoglycemia rates (53).

A study in Tanzania reported that, younger age, having the mother as the primary care giver, better care giver knowledge of diabetes and better adherence to blood glucose monitoring regimen were associated with better glycemic control(32). In other ways, Retrospective cohort study conducted among 188 participants in Tunisia shown that, mean HbA1c was higher in T1DM patients with negative correlation among age at onset of diabetes(15).Study in Uganda also reported that, poor nutrition knowledge among care givers especially on carbohydrate counting was associated with poor glycemic control among type 1 diabetic children(54).

Whereas, in Ethiopia specifically in Gojjam, Age <5 years among T1DM children were significantly associated with the occurrence of acute complication(31).

2.2.2. Comorbidity associated predictors of glycemic control

A study indicates that, T1DM had an association with another non communicable diseases in both sex, age groups(49). A population study in Denmark in 2018 indicated that, psychiatric comorbidity in children with T1DM increases the risk of poor metabolic level during the first 24 months after onset of the diabetes and it was found to be a risk factor for hospitalization with diabetic keto acidosis(55,56).

A clinical based prospective cohort study in T1DM patient recognized that, impairment of glucose metabolism and deteriorating diabetes control can be related to anemia, renal insufficiency, vitamin D deficiency, different type of infection and other autoimmune diseases (57–60).But in Iraq celiac disease was not significantly association with glycemic control among type 1 diabetic children(47).Other synthesis of data in brazil published on October 2019 also recognized that, in addition to the usual community disease, other different type of infections have been occurred predominately in diabetic patients particularly when there is in adequate glycemic control and most of the infections can be sever in this patients and interferes glucose control with high possibility of leading to complication(18).Poor glycemic control is associated with a significantly increased risk of both microvascular and cardio vascular complication(61).Evidence indicated that, improved glycemic control reduces the risk of both micro and macro vascular complication(60). Despite improvements in glycemic control and reduced microvascular complications by using intensive insulin therapy, weight gain becomes frequently encountered side effect that may contribute to increased cardio metabolic risk such as increased dyslipidemia and blood

pressure(62).In line with this, another controlled study also reported that,T1DM patients with normal weight preschool children have better glycemic control with short period of time than age matched overweight children(63,64).

Retrospective cohort study conducted in Tunisia publicized that, mean HbA1c was higher in T1DM patients subjects with lipohyperthrophy and those with known celiac disease(15).

Survival study in Ethiopia made known that, clients with T1DMs had high hazard of death with the main predictive factors for survival time of diabetic patients such as hypertension, over weight, high blood cholesterol level(65). Another study in Ethiopia also shows that ,glycemic control was significantly associated with predictors like upper respiratory tract infection(URTI) and preceding gastroenteritis(31).

2.2.3. Personal and clinical predictors of glycemic control

A prospective study in developed nation verified that, clinical related factors may call for proactive efforts to prevent worsening, while family assignation and psychological symptoms could be taken as chances for clinical intervention to promote better diabetes management and control in older children(44,55).

A healthy diet in children using low gastric load and dietary instruction based on the food pyramid/carbohydrate count integrated in to insulin therapy to the usual eating and exercise pattern can significantly results better glycemic control within expected time(35,64,66).

A follow up study conducted in united states(2019) strongly suggest that, early initiation of diabetes devices could improve glycemic control in children who were newly diagnosed T1DM with in the first 12 months of diabetes(38). The progressive nature of the disease requires regular monitoring of the glycaemia(12). The results of self-monitoring aids, the diabetics in decision making on the food, exercise and use of medication including dose adjustment(6,34,35,37). Optimal glycemic control with insulin therapy for T1DM is fundamental which should be aiming to achieve good glycemic control with achievement of HbA1c <7.5%, pre meal self-monitoring blood glucose (SMBG) of 90-130mg/dl, bedtime SMBG of 100-140mg/dl, mean blood glucose level of 120-160 mg/dl(66,67). The use of Pediatrics continuous glucose monitoring(CGM) increased the chance of lowering HbA1c/average FBG level and improves time in target regardless of insulin delivery modality (68-70). However, this novel techniques like CGM including insulin

pump are not accessible for most of the clients(70).In addition to this, there is limited availability of experts to manage this complex disease(10,20,52) .As a result, the need for clients to travel long distance is a must in order to get guidance. But it is usually not feasible at regular intervals (71). Prospective Follow-up study in Germany, Austria, and Luxembourg among Patients with T1DM <15 years old confirmed that, insulin pump compared with insulin injection therapy was associated with lower risk of hypoglycemia and DKA; which ultimately brings better glycemic control in short period of time(37).In other ways, numerous daily subcutaneous insulin injections route using syringe and vial and sometimes insulin pens remains the most predictable route for insulin administration among diabetic children(72). However, this routes have been associated with compromised client compliance, fear of injection and unacceptability; which results un ability of achieving optimal glycemic control on time; again which endorse the demand for another route of insulin administration(72).

A recent retrospective cohort study in Jordan also revealed that, poor metabolic control was associated with number of clinic visit, frequency of blood glucose testing per day, absence of carbohydrate count, body mass index(BMI),dietary noncompliance, not receiving insulin at school(50).But in Iraq body mass index(BMI) was not significantly association with glycemic control among type1 diabetic children(47).

Chronic care health system in SSA have been established significantly in the last decade, but the potential for managing and approaching diabetes case remains still unsatisfactory(73). This poor glycemic control is mainly determined by diabetes duration(73)Particularly for those recently diagnosed cases as compared from diabetes diagnosed more than 2 years as it was reported by study in Cameron in the year of 2017(74,75). But, in Tanzania children with diabetes duration less than one year were associated with better glycemic control(32). Which was slightly different on the finding conducted at Cameron(75). Retrospective cohort study in Tunisia shown that, mean HbA1c was higher in T1DM patients with poor compliance to insulin therapy, in those with less than 3 clinic visit per year, but no relationship observed with number of daily insulin injection(15). A retrospective record review in Nigerian teaching hospital identified that, having more than one complication, lipid abnormality, retinopathy, ethnicity, body mass index(BMI) and self-reported physical activity in adolescents were independently associated with optimal glycemic control(11,64). Another study in Sudan revealed that, relationship was not observed between

nutritional status and glycemic control. However, there was an association between socioeconomic status and glycemic control(76).

Survival study among diabetic patients in Ethiopia reported that, clients with T1DMs had high hazard of death with the main predictive factors for survival time of diabetic patients such as hypertension, diabetic complications, overweight, high blood cholesterol level and other substance abuse related behaviors especially on adolescents; with the recommendation of regular checkup of blood glucose level and proper use of insulin to achieve optimal glycemic control in short period of time(65).Another study in Ethiopia acknowledged that, non-adherence and in appropriate insulin storage were significant predictors for the occurrence of acute complication particularly diabetic keto acidosis(DKA)(31).

Generally, the rising of T1DM and poor glycemic control in children implies that, there is a need for continuous monitoring of incidence thereby, approving prevention strategies to fight against diabetes problem in children(77). However, achieving and sustaining a good glycemic control among diabetic children in the follow up clinic is too challenging; specially in developing countries even with more intensive education on the risk factors for diabetes care, as well as launching hospital guide lines for diabetes management(78). As a result, identification of other prognostic factors that hinders time to first optimal glycemic control where indicated.

2.3. Conceptual frame work

This conceptual frame work has been adapted from previously conducted study on predictors/associated factors that affect glycemic control either negatively or positively. Demographic factors like age, institutional related variables like number of clinic visit and treatment related variables such as adherence, noncompliance and other self-monitoring practice including other concomitant disease may affect time to first optimal glycemic control as shown on the fig 1 bellow.




Figure 1:Time to glycemic control concept map among type 1 diabetic children in Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021; adapted from(,36,40,50,79)

3. METHODS AND MATERIALS

3.1. Study area and period

The study was conducted in Bahir Dar city; located 565Km far from Addis Ababa, the capital city of Ethiopia, at Amhara national regional state, North West Ethiopia. In Bahir Dar city there are two public referral hospitals, one primary hospitals, ten health center and four private hospitals. And this study was conducted in the two public referral hospitals, namely: Felege Hiwot comprehensive specialized referral hospital (FHCSH) and Tibebe Ghion specialized teaching hospital (TGSTH). Each of this hospital can be expected to serve for more than 10 million populations coming from Bahir Dar city, west Gojjam zone, east Gojam zone, awi zone, north and south wollo zones, south& north Gondar zones, partial part of Benshangul Gumuz and Oromia region. FHCSH has currently a total of 1431 man power in each discipline with 500 formal beds, 11 wards, 39 clinical and non-clinical departments /service unit / providing Diagnostic, curative, Rehabilitation and preventive service at outpatient & inpatient based. Similarly TGSTH is a teaching hospital under Bahir Dar University College of medicine and health sciences that has 459 bed capacity and with around 14 outpatient departments.

Apart from other services both referral hospitals provide diabetic treatment services by nurse practitioners, pediatrics residents and pediatricians.

The study period address from1stJanuary, 2016 to February 30 /2021.

3.2. Study design

An institution based retrospective follow up study was employed

3.3. Source, study population and study unit

3.3.1. Source population

The source population were all type 1 diabetes mellitus children<15 years old who had follow up at diabetes clinic of the two referral hospitals.

3.3.2. Study population

The study population were all type 1 diabetes mellitus children <15 years old who were on follow up during the study period.

3.3.3. Study unit

All type one diabetic children's chart that were selected randomly for investigation

3.4. Inclusion and exclusion criteria

3.4.1. Inclusion criteria

Children age less than 15 years old and diagnosed with T1DM with regular follow up and had at least one HbA1c and/or a three month consecutive measurements of fasting blood sugar (FBS) with clear date of diagnosis between January 1/2016 to February 30/2021 were included.

3.4.2. Exclusion criteria

Children's medical record/chart with incomplete information (such as HbA1c/average FBG and other relevant predictors like age with date of diagnosis, sex, treatment modality, frequency of follow up visit and last visit health condition of the children), those having less than 3 month follow up during the study period and those cases transferred in with unclear date of diagnosis from other institution were excluded from the study.

3.5. Sample size determination

Sample size was determined by double proportion formula after taking of predictors associated to optimal glycemic control from previous study conducted by retrospective cohort design (50)with the help of epi info version 7 by considering the following statistical assumptions: 95% Confidence Interval (CI), power 80%, percent of outcome in unexposed group 8.93%, risk ratio 0.253, marginal error 5% (50). The calculated total sample size is 378, then by adding 10% for data incompleteness from the client chart, the final sample size became 416.

As shown below in the table 1 from major independent predictors conducted to identify predictors associated with glycemic control among diabetic children by retrospective cohort study design carbohydrate count yields relatively adequate and feasible sample size to perform this study.

Table 1: Calculated sample size to estimate time to first optimal glycemic control among type

one diabetic children in Bahir Dar	city public referral he	ospitals, North West Et	hiopia, 2021
Variable	Proportion	Total sample size	

Variable		Proportion	Total sample size
Carbohydrate	Yes	P1 8.93%	378(50)
count	No	P2 2.3%	
		RR 0.253	
Age	≤5	P1 0.1%	182(50)
	>5-10&10-15	P2 26.5%	
		RR 0.004	

Where

P1: is percent of exposed with outcome of glycemic control

P₂: is percent of non-exposed with outcome of glycemic control.

RR: risk ratio

Finally 416 type 1 diabetic children were recruited among the study population in the study area.

3.6. Sampling technique and procedure

The study participants were selected from the registration book. The medical records of children who were on follow up with type one diabetes mellitus from January 2016 to February 2021 were selected. A total of 721 children were recorded from the registration book of the two referral hospitals (sampling frame). Of which 416 cards were sampled using a simple random sampling technique by a computer generating method. Finally, cards that fulfilled the criteria were reviewed.

3.7. Study variables

3.7.1. Dependent variables

Time to first optimal glycemic control

3.7.2. Independent variables

Socio demographic (age, gender, Residence); Institutional related variable (frequency of clinic visit); Diabetic related variables (duration of diabetes, diabetes related complication.); Comorbidities (preceding infections and other pathology) and treatment related variables (insulin therapy and adherence, noncompliance and other self-monitoring practice)

Age of the participants, frequency of glycemic control, body mass index and duration of diabetes were categorized in to groups in order to alien with the other literatures (36,40,50)

3.8. Operational definitions

Optimal glycemic control: Optimal glycemic control is defined as the three consecutive month HbA1c <7.5% and/or average FBG of 80–150 mg/dl with more or less stringent glycemic goals for individual clients based on age/life expectancy, comorbid condition, advanced complication, hypoglycemia unawareness and individual patient considerations (6-8,80).

Event: Achieving first optimal glycemic control during the study period

Survival time: The time starting from date of diagnosis to first optimal glycemic control was determined for each participant

Censoring: Patients died, lost to follow up, transferee out, and complete the follow up period without achieving optimal glycemic control

Time to event: Time between diagnosis up to achieving first optimal glycemic control or censoring with measure of interest in month

Carbohydrate counting: Practicing healthy diet at home by non-refined carbohydrate utilization and eating consistent amount of food regularly with application of food pyramid as a meal planning tool to optimize blood sugar level (35).

3.9. Data collection procedure

The data were collected from patients chart that visit Felege Hiwot comprehensive specialized referral hospital and Tibebe Ghion specialized teaching hospital. Data that were relevant to measure the association between times to first optimal glycemic control among diabetic children were collected by two BSc nurses supervised by one senior nurse having second degree in public health.

Patient records were retrieved using their medical registration number identified in the total DM case load in the logbook of registration follow up form. Then medical registration number (MRN) of all diabetic pediatric patient were sorted. After that, the sample selection mechanism was simple random sampling technique, in which each of the patients had equal chance of being selected to be part of study.

A structured data extraction tool adapted by considering study variables such as socio demographic, personal and clinical predictors from patients' charts.

3.10. Data quality assurance

Training was given for data collectors and supervisors about the objective and process of data collection by the principal investigator. Pretest was done on 5 % of sample size. Then pretested data abstraction tool/check list that comprises of questions to measure the relevant variables were used to collect the necessary data from the patient medical chart by those trained data collectors. Data quality was also assured by designing proper data abstraction tool and through continuous supervision. All collected data were checked for completeness and clarity.

3.11. Data processing and statistical analysis

The collected data was coded, enter, cleaned and stored into Epi-data version 3.1 and exported into STATA 14.2 statistical software for analysis. Descriptive statistics were presented with frequency tables, Kaplan Meier (KM) plots and median survival times. Months are used as a time scale to calculate time to first optimal glycemic control. The outcome of each participant was dichotomized in to censured or event (first optimal glycemic control)

Kaplan-Meier technique was used to measure survival experience of diverse groups of patients by using survival curves. Log-rank test was used to assess significant difference among survival distributions of groups for equality. After performing the Cox-proportional hazard regression, model goodness-of-fit was checked by Cox Snell residuals & assumptions was checked by using Shenfield residual test and graphically by using log minus log function survival curves.

Bivariable analysis was performed to calculate crud hazard ratio (CHR) and to screen out potentially significant independent variables at p value < 0.25 level of significance.

Association between the significant independent variables and the time to first optimal glycemic control was assessed using multivariable Cox Proportional Hazard (PH) model.

Adjusted hazard ratio (AHR) and 95% CI for HR were used to test significance and interpretation of results.

Variables with p-value < 0.05 were considered as statistically associated with the time to first optimal glycemic control in months.

3.12. Ethical considerations

Ethical clearance was obtained from the institutional review board (IRB) of Bahir Dar University (IRB number 01-008).Written supportive letter was taken from pediatrics department of the hospitals on behalf of the patients. This study had no any danger or negative consequences for the study participants. Medical record numbers were used for the data collection and personal identifiers of the client were not used in this research report. Access to collected information was limited to the principal investigator and confidentiality had preserved throughout the time.

3.13. Dissemination of the result

The finding of this study is presented to Bahir Dar university department of nursing as partial fulfillment of master's degree in pediatrics and child health nursing. The finding will be also announced to Felege Hiwot comprehensive specialized referral hospital as well as Tibebe Ghion specialized teaching hospital. Hard and soft copies will be available in the library of Bahir Dar University, for graduate students and for other researchers and readers.

4. RESULT

4.1. Socio demographic characteristics

Four hundred sixteen (416) medical records were reviewed; off which, thirty one (7.5%) cases were excluded from the study due to pertinent data being missing. As a result, 385 clients were included in the study which is 92.5% in response rate.

Mean age of the study participant was 8.2 ± 4.7 years with 2.4 years mean duration of diabetes. More than half of the patients were male (53%) and proportion of first optimal glycemic achievement among male is (72%) which is almost proximal to female (71.3%).

Majority of the patients (64.7%) were from rural area. However, the Proportion of patients who achieved first optimal glycemic control among rural is (68.7%) which is lower than clients from urban area residents (77.2%).

Those clients having >4 clinical visit for the last year of their follow up had higher proportional glycemic control (82.3%) than clients having clinical visit <=4(663%). (Table 2).

Table 2: sociodemographic and institution related variable with censuring and event status among type 1 diabetic clients, Bahir Dar, 2021(n=385)

Variables	Category	Event and censured status			
		No. of event	No.of censured	Total	
Age group in years	<=5	83(68%)	39(32%)	122(31.7%)	
	>5-10	79(85.9%)	13(14.1%)	92(23.9%)	
	>10-14	114(66.7%)	57(33.3%)	171(44.4%)	
Sex	Male	147(72%)	57(27.9%)	204(53%)	
	Female	129(71.3%)	52(28.7%)	181(47%)	
Resident	Urban	105((77.2%)	31(22.8%)	136(35.3%)	
	Rural	171(68.7%)	78(31.3%)	249(64.7%)	
Number of clinic	<=4	169(66.3%)	86(33.7%)	255(66.2%)	
visit during the last year of follow up	>4	107(82.3%)	23(17.7%)	130(33.8%)	

4.2. Median survival time to first optimal glycemic control

The estimated median survival time to achieve first glycemic control was 8 months with inter quartile range of (6.9-8.9).

The median survival time to first optimal glycemic control among type one diabetic children were varied by various categories of predictors. For example, the median survival time to achieve first optimal glycemic control among under 5 children was 6.8 where as in above 5-10 and >10-14 years was 8, 8.5 respectively. (Table 5).

4.3. Incidence rate of optimal glycemic achievement rate

From 385 study participants, 276(71.7%) of the clients have achieved glycemic control with mean value of FBG&HA1c (112±3mg/dl, 5.6%) respectively; whereas 109(28.3%) were censored. The lowest and the highest length of follow up were 2.9 and 36.4 months respectively, and the total person-time risk was 3373 months.

The overall first optimal glycemic control rate was 8.2(95%CI: 7.2-9.7) per 100 person/month observation. Optimal glycemic achievement rate among male and female children with type 1 diabetes was 7.9(95%CI: 6.7-9.3) per 100 person/month and 8.4(95%CI: 7.1-10.0) per 100 person/month observation respectively which is nearly comparable in both sex.

4.4. Diabetes related variables

Concerning complication,83.4% of the patients had history of one or more diabetes related complication .Majority of the clients had diabetic keto acidosis(DKA)(81%) including the episodes at the time of diagnosis followed by hypoglycemia(19.7%),other complication(4.9%) and chronic complication(0.8%).mixed insulin(lent ®ular) drugs had given for the majority of the patients(62.9%)during the initiation of treatment as compared to other regimens like NPH with regular and NPH alone(20%,17.1%)respectively.

The proportion of patients who achieved optimal glycemic control is relatively higher among those with no history of diabetes related complication (76.6%) as compared to those with history of complication (70.7%).(Table 3).

Variables	Category	Event and censured status			
				total	
		No. of event	No.of		
			censured		
History of diabetes	NO	49(76.6%)	15(23.4%)	64(16.6%)	
related complication	Yes	227(70.7%)	94(29.3%)	321(83.4%)	
DKA	NO	53(72.6%)	20(27.4%)	73(19%)	
	Yes	223(71.5%)	89(28.5%)	312(81%)	
Hypoglycemia	NO	211(68.3%)	98(31.7%)	309(80.3%)	
	Yes	65(85.5%)	11(14.5%)	76(19.7%)	
Chronic complication	NO	274(71.7%)	108(28.3%)	382(99.2%)	
	Yes	2(66.7%)	1(33.3%)	3(0.8%)	
Other complication*	NO	259(71.9%)	101(28%)	360(93.5%)	
	Yes	12(63.2%)	7(36.8%)	19(4.9%)	
More than one	NO	245(72%)	95(27.9%)	340(88.3%)	
complication	Yes	31(68.9%)	14(31.1%)	45(11.7%)	
Diabetes related	NO	52(74.3%)	18(25.7%)	70(18.2%)	
hospitalization	Yes	224(71.1%)	91(28.9%)	315(81.8%)	
Insulin Regimen	Mix(regular &lent)	154(63.6%)	88(36.4%)	242(62.9%)	
	NPH ®ular	70(90.9%)	7(9%)	77(20%)	
	NPH only	52(78.8%)	14(21.2%)	66(17.1%)	
Non Compliance (dose	NO	219(85.5%)	37(14.5%)	256(66.5%)	
omission, drug skipping, inappropriate insulin storage)	Yes	56(43.8%)	72(56.3%)	128(33.2%)	
Duration of diabetes	<2	75(0.5%)	75(0.5%)	150(39%)	
	[2-4)	80(80.8%)	19(19.2%)	99(25.7%)	
	>=4	121(89%)	15(11%)	136(35.3%)	
Adherence to diabetic	NO	91(46.7%)	104(53.3%)	195(50.6%)	
care	Yes	185(97.4%)	5(2.6%)	190(49.4%)	
Family history of	NO	238(71.7%)	94(28.3%)	332(86.2%)	
diabetes mellitus	Yes	38(71.7%)	15(28.3%)	53(13.8%)	

Table 3: Diabetes related variable with censuring and event status among type 1 diabetic clients, Bahir Dar, 2021(n=385)

*other complication includes insulin injection site swelling together with lipohypertrophy and dystrophy

4.5. Comorbidity related variables

In regard to comorbidity, 69.6% of the patients had history of comorbid illness and only 30.4% of them didn't have recognized history of comorbid illness. Majority of the clients had malnutrition (38.7%) followed by pneumonia (16.1%), urinary tract infection (13.8%), acute gastro enteritis (10.1%), fungal infection (7%) and upper respiratory tract infection (6.5%).Nearly half (48%) of the patients had more than one comorbid illness.

The proportion of clients who achieved first optimal glycemic control is higher among those with no history of comorbid illness (74.4%) than those with one or more comorbid illness (70.5%). (Table 4).

Category	Event and censured status		total
	No. of event	No.of censured	
NO	87(74.4%)	30(25.6%)	117(30.4%)
Yes	189(70.5%)	79(29.5%)	268(69.6%)
NO	273(72%)	106(28%)	379(98.4%)
Yes	3(50%)	3(50%)	6(1.6%)
NO	272(71.8%)	107(28.2%)	379(98.4%)
Yes	4(66.7%)	2(33.3%)	6(1.6%)
NO	244(73.5%)	88(26.5%)	332(86.2%)
Yes	32(60.4%)	21(39.6%)	53(13.8%)
NO	234(72.4%)	89(27.6%)	323(83.9%)
Yes	42(67.7%)	20(32.3%)	62(16.1%)
NO	264(72.5%)	100(27.5%)	364(94.5%)
Yes	15(60%)	10(40%)	25(6.5%)
NO	248(71.7%)	98(28.3%)	346(89.9%)
Yes	28(71.8%)	11(28.2%)	39(10.1%)
	NO Yes NO Yes NO Yes NO Yes NO Yes NO Yes NO Yes NO	No. of event NO 87(74.4%) Yes 189(70.5%) NO 273(72%) Yes 3(50%) NO 272(71.8%) Yes 4(66.7%) NO 244(73.5%) Yes 32(60.4%) NO 234(72.4%) Yes 42(67.7%) NO 264(72.5%) Yes 15(60%) NO 248(71.7%)	No. of event No.of censured NO 87(74.4%) 30(25.6%) Yes 189(70.5%) 79(29.5%) NO 273(72%) 106(28%) Yes 3(50%) 3(50%) Yes 3(50%) 3(50%) NO 272(71.8%) 107(28.2%) Yes 4(66.7%) 2(33.3%) NO 244(73.5%) 88(26.5%) Yes 32(60.4%) 21(39.6%) NO 234(72.4%) 89(27.6%) NO 264(72.5%) 100(27.5%) NO 264(72.5%) 100(27.5%) NO 248(71.7%) 98(28.3%)

Table 4: comorbid illness related variable with censuring and event status among type 1 diabetic clients, Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021(n=385)

Malnutrition	NO	191(71.5%)	76(28.5%)	267(69.4%)
	Yes	107(71.8%)	42(28.2%)	149(38.7%)
Autoimmune disease	NO	270(72.2%)	104(27.8%)	374(97.1%)
	Yes	6(54.5%)	5(45.5%)	11(2.9%)
Tuberculosis(TB)	NO	273(72%)	106((28%)	379(98.4%)
	Yes	3(50%)	3(50%)	6(1.6%)
Meningitis	NO	274(73%)	101(26.9%)	375(97.4%)
	Yes	2(20%)	8(80%)	10(2.6%)
Malaria	NO	268(72%)	104(28%)	372(96.6%)
	Yes	8(61.5%)	5(38.5%)	13(3.4%)
Fungal infection	NO	262(73.2%)	96(26.8%)	358(93%)
	Yes	14(51.9%)	13(48.1%)	27(7%)
More than one comorbid	NO	146(73%)	54(27%)	200(51.9%)
illness	Yes	130(70.3%)	55(29.7%)	185(48%)

Table 4: comorbid illness related variable with censuring and event status among type 1 diabetic clients, Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021(n=385 cont..

4.6. Survival estimates for time to first optimal glycemic control

The survival status of children with type 1 diabetes was estimated by the Kaplan-Meier survival curve.

The curve tends to decrease rapidly with in the first one year indicating that most children achieved first optimal glycemic control within this time (Figure 2).




Figure 2: Kaplan-Meier survival estimate of time to first optimal glycemic control among type 1 diabetic children having follow up at Bahir Dar city public referral hospitals, 2021

The survival estimates of clients were varied in relation to different predictors. (Figure 3).




Figure 3: Kaplan Meier survival estimate for time to optimal glycemic control among type 1 diabetic children with history of comorbidity in Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021

4.7. Comparison of survival experience

The long rank test was used to assess differences in equality of survival distribution among diverse groups. The median survival time to achieve first optimal glycemic control among clients in the age groups of $\langle =5 \rangle$ years showed shorter median time to achieve first optimal glycemic control (6.8 months) as compared with patients whose age group between 6-10 years (8months) and 11-14 years (8.5 months).and the survival time was significantly different among the age groups(X²(2)) = 6.05, P-value = 0.0486).whereas, the median survival time to achieve first optimal glycemic control among male participant showed relatively longer time (8.5 months) than females (7.2 months).But the long rank test was not statistically significant(X²(1))=0.92,p-value=0.3378). (Table 5).

Variables	Category	Test of equality ov	er groups			
		Median survival	Mean survival	Log ran	ık	
		time(months)	time(months)	\mathbf{X}^2	DF	P-value
Age group in years	<=5	6.8	8.5	6.05	2	0.0486
	>5-10	8	9.8			
	>10-14	8.5	10.2			
	Male	8.5	9.9	0.92	1	0.3378
Sex	Female	7.2	9.2			
	Urban	7.6	9.6	0.02	1	0.8911
Resident	Rural	8	9.6			
Education status of	KG/not started	7.1	8.9	11.23	2	0.0036
children	Primary school	9	10.6			
	High school	14.8	13			
Family history of	NO	7.8	8.7	0.28	1	0.5987
diabetes	Yes	8	9.4			
Number of clinic	<=4	7.7	8.5	1.31	1	0.2521
visit	>4	8	9.4			
Adherence to diabetic	NO	14.9	10.9	131.75	1	< 0.0001
care	Yes	5.7	6.7			
Insulin regimen	Mixed(lent	7.1	8.4	15.87	2	0.0004
U	&Regular)					
	NPH& Regular	9.2	10.1			
	NPH only	9.8	12.3			

Table 5: comparisons of optimal glycemic control among type 1 DM clients, Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385)

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	hospitals, Northwest, I	Ethiopia, 2021(n=.	385) cont				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Duration of	< 2	5.5	6.2	54.93	2	< 0.0001
S=411.111.4Carbohydrate count YesNO10.211.140.261<0.0001	Diabetes in year	[2-4)					
NoncomplianceYes5.56.9NoncomplianceNO 6.4 8.2 42.30 1<0.0001	j						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Carbohydrate count				40.26	1	< 0.0001
Note Diabetes related acute complicationYes14.8 7.714.9 9.52.9410.0862Diabetes related acute complicationNO7.7 Yes9.5 80.1210.7289 9.6Diabetic ketoacidosis YesNO6.2 Yes9.5 80.1210.7289 0.59Chronic complicationNO7.8 Yes8.7 12.10.5910.4434ComplicationNO7.8 Yes9.5 10.21.0210.3131Other complication YesNO7.8 Yes9.3 10.20.2110.6448More than one complication YesNO6.3 8.98.3 10.10.2110.6448Wasting WastingNO8.2 Yes8.910.10.00100.0010Wasting YesNO7.8 9.88.80.1510.7019Yes9.88.4Cardio vascular disease YesNO7.7 9.88.90.3110.9229More than one YesNO7.78.90.890.3460Yes98.1Acute gastro enteritis YesNO7.7 7.79.50.2110.6448							
Diabetes related acute complicationNO Yes7.7 89.5 9.62.9410.0862Diabetic ketoacidosis VesNO Yes6.2 89.60.1210.7289Chronic complicationNO Yes7.8 12.18.7 18.50.5910.4434Other complicationNO Yes7.8 10.29.5 11.31.0210.3131More than one complicationNO Yes7.8 10.29.3 11.30.2110.6448More than one complicationNO Yes7.8 8.99.3 100.2110.6448More than one complication YesNO 8.96.3 8.38.3 10.8510.0010Wasting diseaseNO Yes8.910.110.3003WastingNO Yes7.8 8.98.80.1510.7019Yes9.88.4Cardio vascular diseaseNO Yes7.7 9.88.90.0110.9229PneumoniaNO Yes7.7 9.48.90.890.3460Yes98.11.00.1524More than oneNO Yes7.7 Yes9.42.0510.1524More than oneNO Yes7.7 Yes9.50.2110.6448	Noncompliance				42.30	1	< 0.0001
acute complicationYes89.6Diabetic ketoacidosisNO Yes6.2 89.5 9.60.1210.7289Chronic complicationNO Yes7.8 12.18.7 18.50.5910.4434Other complicationNO Yes7.8 10.29.5 11.31.0210.3131More than one complicationNO Yes7.8 8.99.3 100.2110.6448More than one complication YesNO 8.97.8 10.19.30.2110.6448More than one complication YesNO 8.98.3 10.11.0210.6448Wasting diseaseNO Yes7.8 8.98.91.0710.3003Wasting diseaseNO Yes7.88.80.0110.9229More than one YesNO7.88.80.0110.9229Massing diseaseNO Yes7.78.90.890.3460Pneumonia MO7.778.90.890.3460Yes98.11.150.1524More than oneNO7.79.42.0510.1524More than oneNO7.79.50.2110.6448							
Diabetic ketoacidosis Chronic complicationNO Yes 6.2 8 9.6 12.1 9.5 9.6 9.6 0.59 0.12 1 1 0.7289 0.4434Other complicationNO Yes 7.8 12.1 9.5 18.5 1.02 11.3 1 0.59 0.4434 Other complicationNO Yes 7.8 10.2 9.5 11.3 1.02 0.21 1 0.6448More than one complicationNO Yes 7.8 8.9 9.3 10 0.21 1 0.6448More than one complicationNO Yes 7.8 8.9 9.3 10 0.21 1 0.6448More than one complication YesNO 8.9 7.8 10.1 9.3 0.21 1 0.6448Wasting Mo GeaseNO Yes 7.8 9.8 8.9 1.07 1 0.3003Wasting Mo diseaseNO Yes 7.8 9.8 8.8 8.4 0.01 1 0.9229Pneumonia diseaseNO Yes 7.7 9.8 8.9 0.01 1 0.9229Pneumonia YesNO Yes 7.7 9.4 2.05 1.07 1 0.1524Acute gastro enteritis YesNO Yes 7.7 9.5 0.21 1 0.6448					2.94	1	0.0862
$\begin{array}{c cccc} & Yes & 8 & 9.6 \\ Chronic \\ complication & Yes & 12.1 & 18.5 & 0.59 & 1 & 0.4434 \\ \hline \\ Other complication & NO & 7.8 & 9.5 & 1.02 & 1 & 0.3131 \\ Yes & 10.2 & 11.3 & 0.21 & 1 & 0.6448 \\ \hline \\ More than one & NO & 7.8 & 9.3 & 0.21 & 1 & 0.6448 \\ complication & Yes & 8.9 & 10 & 1 & 0.0010 \\ \hline \\ History of & NO & 6.3 & 8.3 & 10.85 & 1 & 0.0010 \\ comorbidity & Yes & 8.9 & 10.1 & 0.85 & 1 & 0.0010 \\ \hline \\ Wasting & NO & 8.2 & 8.9 & 1.07 & 1 & 0.3003 \\ Yes & 6.8 & 8.6 & & & \\ Stunting & NO & 7.8 & 8.8 & 0.15 & 1 & 0.7019 \\ Yes & 9.8 & 8.4 & & & \\ \hline \\ Cardio vascular \\ disease & Yes & 12.1 & 10.2 & & & \\ Yes & 9.8 & 8.4 & & & \\ Pneumonia & NO & 7.7 & 8.9 & 0.89 & 0.3460 \\ Yes & 9 & 8.1 & & & \\ \hline \\ Acute gastro enterits & NO & 7.7 & 9.4 & 2.05 & 1 & 0.1524 \\ Yes & 10.2 & 11.5 & 0.21 & 1 & 0.6448 \\ \hline \end{array}$	acute complication	Yes	8	9.6			
$\begin{array}{c cccc} & Yes & 8 & 9.6 \\ Chronic \\ complication & Yes & 12.1 & 18.5 & 0.59 & 1 & 0.4434 \\ \hline \\ Other complication & NO & 7.8 & 9.5 & 1.02 & 1 & 0.3131 \\ Yes & 10.2 & 11.3 & 0.21 & 1 & 0.6448 \\ \hline \\ More than one & NO & 7.8 & 9.3 & 0.21 & 1 & 0.6448 \\ complication & Yes & 8.9 & 10 & 1 & 0.0010 \\ \hline \\ History of & NO & 6.3 & 8.3 & 10.85 & 1 & 0.0010 \\ comorbidity & Yes & 8.9 & 10.1 & 0.85 & 1 & 0.0010 \\ \hline \\ Wasting & NO & 8.2 & 8.9 & 1.07 & 1 & 0.3003 \\ Yes & 6.8 & 8.6 & & & \\ Stunting & NO & 7.8 & 8.8 & 0.15 & 1 & 0.7019 \\ Yes & 9.8 & 8.4 & & & \\ \hline \\ Cardio vascular \\ disease & Yes & 12.1 & 10.2 & & & \\ Yes & 9.8 & 8.4 & & & \\ Pneumonia & NO & 7.7 & 8.9 & 0.89 & 0.3460 \\ Yes & 9 & 8.1 & & & \\ \hline \\ Acute gastro enterits & NO & 7.7 & 9.4 & 2.05 & 1 & 0.1524 \\ Yes & 10.2 & 11.5 & 0.21 & 1 & 0.6448 \\ \hline \end{array}$		NO	<. 2	o -	0.10		
$\begin{array}{c cccc} Chronic complication & NO & 7.8 & 8.7 & 0.59 & 1 & 0.434 \\ \hline complication & NO & 7.8 & 9.5 & 1.02 & 1 & 0.3131 \\ \hline Other complication & NO & 7.8 & 9.3 & 0.21 & 1 & 0.6448 \\ complication & Yes & 8.9 & 10 & 10 \\ \hline History of & NO & 6.3 & 8.3 & 10.85 & 1 & 0.0010 \\ \hline comorbidity & Yes & 8.9 & 10.1 & 0.85 & 1 & 0.0010 \\ \hline Wasting & NO & 8.2 & 8.9 & 1.07 & 1 & 0.3003 \\ \hline Yes & 6.8 & 8.6 & & & \\ Stunting & NO & 7.8 & 8.8 & 0.15 & 1 & 0.7019 \\ \hline Yes & 9.8 & 8.4 & & & \\ \hline Cardio vascular \\ disease & Yes & 12.1 & 10.2 & & & \\ Pneumonia & NO & 7.7 & 8.9 & 0.89 & 0.3460 \\ \hline Yes & 9 & 8.1 & & \\ Acute gastro enteritis & NO & 7.7 & 9.4 & 2.05 & 1 & 0.1524 \\ \hline More than one & NO & 7.7 & 9.5 & 0.21 & 1 & 0.6448 \\ \hline \end{array}$	Diabetic ketoacidosis				0.12	I	0.7289
ComplicationYes12.118.5Other complicationNO 7.8 9.5 1.02 1 0.3131 More than oneNO 7.8 9.3 0.21 1 0.6448 complicationYes 8.9 10 10.85 1 0.0010 History ofNO 6.3 8.3 10.85 1 0.0010 comorbidityYes 8.9 10.1 0.855 1 0.0010 WastingNO 8.2 8.9 1.07 1 0.3003 StuntingNO 7.8 8.6 $Yes9.88.40.7019Yes9.88.4$					0.50	4	0.4424
Other complication NO 7.8 9.5 1.02 1 0.3131 More than one NO 7.8 9.3 0.21 1 0.6448 complication Yes 8.9 10 10.85 1 0.0010 History of NO 6.3 8.3 10.85 1 0.0010 comorbidity Yes 8.9 10.1 0.85 1 0.3003 Wasting NO 8.2 8.9 10.1 0.3003 Wasting NO 7.8 8.6 . . Stunting NO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4 Cardio vascular NO 7.8 8.8 0.01 1 0.9229 disease Yes 12.1 10.2 Pneumonia NO 7.7 8.9 0.89 .	Chronic				0.59	1	0.4434
Yes10.211.3More than one complicationNO7.89.30.2110.6448More than one complicationYes8.910100.0010History of comorbidityNO6.38.310.8510.0010WastingNO8.28.910.110.3003WastingNO8.28.91.0710.3003Yes6.88.68.6 $$	complication	Yes	12.1	18.5			
Yes10.211.3More than one complicationNO7.89.30.2110.6448More than one complicationYes8.910100.0010History of comorbidityNO6.38.310.8510.0010WastingNO8.28.910.110.3003WastingNO8.28.91.0710.3003Yes6.88.68.6 $$							
More than one complicationNO 7.8 9.3 0.21 1 0.6448 More than one comorbidityYes 8.9 10 10 0.85 1 0.0010 WastingNO 8.2 8.9 10.1 1.07 1 0.3003 WastingNO 8.2 8.9 1.07 1 0.3003 Yes 6.8 8.6 $$	Other complication	NO		9.5	1.02	1	0.3131
$\begin{array}{cccc} complication & Yes & 8.9 & 10 \\ History of & NO & 6.3 & 8.3 \\ comorbidity & Yes & 8.9 & 10.1 & 10.85 & 1 & 0.0010 \\ \end{array}$		Yes	10.2	11.3			
History of comorbidityNO Yes 6.3 8.9 8.3 10.1 10.85 1 0.0010 WastingNO 8.2 8.9 10.1 1 0.3003 WastingNO 8.2 8.9 1.07 1 0.3003 Yes 6.8 8.6 0.15 1 0.7019 StuntingNO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4 0.01 1 0.9229 diseaseYes 12.1 10.2 0.89 0.3460 PneumoniaNO 7.7 8.9 0.89 0.3460 Yes 9 8.1 0.1524 10.2 11.5 More than oneNO 7.7 9.4 2.05 1 0.1524	More than one	NO	7.8	9.3	0.21	1	0.6448
comorbidityYes8.910.1WastingNO8.28.91.0710.3003Yes6.88.6 \cdot \cdot \cdot \cdot StuntingNO7.88.80.1510.7019Yes9.88.4 \cdot \cdot \cdot \cdot Cardio vascular diseaseNO7.88.80.0110.9229PneumoniaNO7.78.90.89 \cdot 0.3460Yes98.1 \cdot \cdot \cdot \cdot Acute gastro enteritis YesNO7.79.4 10.22.0510.1524More than oneNO7.79.50.2110.6448	complication	Yes	8.9	10			
WastingNO8.28.91.0710.3003Yes6.88.6StuntingNO7.88.80.1510.7019Yes9.88.4Cardio vascular diseaseNO7.88.80.0110.9229diseaseYes12.110.2PneumoniaNO7.78.90.890.3460Yes98.1Acute gastro enteritisNO Yes7.79.4 11.52.0510.1524More than oneNO7.79.50.2110.6448	History of	NO	6.3	8.3	10.85	1	0.0010
Yes 6.8 8.6 Stunting NO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4	comorbidity	Yes	8.9	10.1			
Yes 6.8 8.6 Stunting NO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4							
StuntingNO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4 1 0.9229 Cardio vascular diseaseNO 7.8 8.8 0.01 1 0.9229 Yes 12.1 10.2 1 0.9229 PneumoniaNO 7.7 8.9 0.89 0.3460 Yes 9 8.1 1 0.1524 Acute gastro enteritisNO 7.7 9.4 2.05 1 0.1524 More than oneNO 7.7 9.5 0.21 1 0.6448	Wasting	NO	8.2	8.9	1.07	1	0.3003
StuntingNO 7.8 8.8 0.15 1 0.7019 Yes 9.8 8.4 1 0.9229 Cardio vascular diseaseNO 7.8 8.8 0.01 1 0.9229 Yes 12.1 10.2 1 0.9229 PneumoniaNO 7.7 8.9 0.89 0.3460 Yes 9 8.1 1 0.1524 Acute gastro enteritisNO 7.7 9.4 2.05 1 0.1524 More than oneNO 7.7 9.5 0.21 1 0.6448	-	Vac	68	86			
Yes9.88.4Cardio vascular diseaseNO7.88.80.0110.9229diseaseYes12.110.210.210.210.3460PneumoniaNO7.78.90.890.3460Yes98.110.210.210.2Acute gastro enteritisNO7.79.42.0510.1524More than oneNO7.79.50.2110.6448		1 05	0.0	0.0			
Yes9.88.4Cardio vascular diseaseNO7.88.80.0110.9229diseaseYes12.110.2 $$	Stunting	NO	7.8	8.8	0.15	1	0.7019
Cardio vascular diseaseNO7.88.80.0110.9229Yes12.110.2PneumoniaNO7.78.90.890.3460Yes98.1Acute gastro enteritisNO Yes7.79.4 10.22.0510.1524More than oneNO7.79.50.2110.6448	C	Vac	0.8	Q /			
diseaseYes12.110.2PneumoniaNO7.78.90.890.3460Yes98.1		105	9.0	0.4			
Pneumonia NO 7.7 8.9 0.89 0.3460 Yes 9 8.1	Cardio vascular	NO	7.8	8.8	0.01	1	0.9229
Pneumonia NO 7.7 8.9 0.89 0.3460 Yes 9 8.1	disease	Vac	12.1	10.2			
Yes 9 8.1 Acute gastro enteritis NO 7.7 9.4 2.05 1 0.1524 More than one NO 7.7 9.5 0.21 1 0.6448		108	12.1	10.2			
Acute gastro enteritisNO Yes7.79.42.0510.1524More than oneNO7.79.50.2110.6448	Pneumonia	NO	7.7	8.9	0.89		0.3460
Acute gastro enteritisNO Yes7.79.42.0510.1524More than oneNO7.79.50.2110.6448		Vac	0	0 1			
Yes10.211.5More than oneNO7.79.50.2110.6448		168	9	0.1			
More than one NO 7.7 9.5 0.21 1 0.6448	Acute gastro enteritis	NO	7.7	9.4	2.05	1	0.1524
		Yes	10.2	11.5			
somethid illness Vac 9.7 0.7	More than one	NO	7.7	9.5	0.21	1	0.6448
comorbid liness i es 8.7 9.7	comorbid illness	Yes	8.7	9.7			

Table 5: comparisons of optimal glycemic control among type 1 DM clients, Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385) cont...

X²:chi-square, DF: Degree of freedom, KG: kindergarten

Regarding adherence, those clients who adhere to the management had shorter duration of time (5.7 months) to achieve first optimal glycemic control than those who didn't adhere towards the

management of the disease(14.9 months). The long rank test was statistically significant($X^2(1)$) = 131.75, P-value <0.0001). As shown in the figure.5, the Kaplan Meier survival function also showed that those clients with adherence have satisfactory survival experience by achieving their glycemic targets early in time. The figure also showed that, clients direct chance of achieving first optimal glycemic control increases for both group as the duration of treatment increases.




Figure.4: survival and hazard function of adherence by time (in month), Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021

Those patients having comorbid illness appears to extend time to first optimal glycemic control. The median survival time to achieve optimal glycemic control was shorter among patients with no history comorbid illness (6.3 months) than patients who had comorbid illness (8.9 months) with statistical significant difference among the group $(X^2(1)) = 10.85$, P-value = 0.0010). (Table 5).

However, no statistically significance difference were shown for sex, residence, family history of diabetes militias ,number of clinic visit ,DKA as presentation and being malnourished in determining time to first optimal glycemic control. (Table 5 & Table 6).

4.8 Results of multivariable cox proportional hazard model

Goodness of fit checked by cox Snell residuals by plotting cox Snell residual against the cumulative hazard function. You can observe in figure 6 as residuals follow unit of exponential distribution or a linear line through the origin with a unit gradient, which indicates a well fitted model to the observed data point and expected value.

Proportional assumption of cox proportional hazard model was tested by using Schoen field residual test and graphically by using log minus log function on Stata version 14.2 (Table 6& Fig 7).Figure 7 indicates that, the survival curve looks like parallel throughout the study time; which shows equitable fitting to the proportional hazard assumption.




Figure.5: Model goodness of fit by cox Snell residual *among type 1 DM clients, Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385)*

Table 6:Test of proportional-hazards assumption by Schoen field residual test (Global test) among type 1 DM clients, Bahir Dar city public referral hospitals, Northwest, Ethiopia, 2021(n=385)

Variables	Rho	X^2	DF	P-value
Age	0.03898	0.39	1	0.5310
Educational status of children	0.06785	1.01	1	0.3138
Primary care giver	0.13921	3.91	1	0.050
Weight the client	0.06590	0.97	1	0.3253
Duration of diabetes	0.01613	0.08	1	0.7784
Insulin regimen	0.12133	2.82	1	0.0934
Dose of insulin	0.07640	1.21	1	0.2715
Frequency of glycemic control	- 0.00730	0.01	1	0.9230
Carbohydrate counting	0.13800	3.28	1	0.0700
Exercise	0.02123	0.09	1	0.7580
Noncompliance	0.08636	1.37	1	0.2410
Adherence	-0.03696	0.25	1	0.6154
Diabetes related complication	0.01547	0.06	1	0.8037
Comorbidity	-0.08886	1.89	1	0.1689
global test		42.48	19	0.5368

Rho: spearman rank correlation coefficients, X2: chi Square, DF: Degree of freedom




Figure.6: log of minus the Log of survival function by comorbidity and carbohydrate count for time to first optimal glycemic control among type 1 diabetic children, Bahir Dar, 2021

The independent variables such as age client educational status, primary care giver, dose of insulin at initiating of treatment, duration of diabetes, first insulin regimen, current insulin regimen, frequency of glycemic control, carbohydrate count, exercise, noncompliance, adherence, diabetes related acute complication, having history of comorbidity were significantly associated with time to first optimal glycemic control at the point less than 0.25 level of significance from bivariable analysis. However, only age, duration of DM, dose of insulin at initiating of treatment, weight, primary care giver, adherence to DM care, carbohydrate counting and history of comorbidity were found to be significantly associated with time to first optimal glycemic control in the multivariable cox regression hazard model less than 5% level of significance.

The presence of interaction among independent variables were checked by multicollinearity test but there was no significant interaction as it was confirmed by the value of variance inflation factor (VIF) which is less than ten.(Annex IV).

Consequently, after adjusting other predictor, the hazard of achieving optimal glycemic control among the age groups >10-14 years were lower by 67.6% as compared with the age groups of the client<=5 years(AHR=0.324,95%CI=0.192-0.546).

Likewise, the hazard of achieving optimal glycemic control among clients with history of comorbid illness was lower by 24.3% compared to clients with no history of comorbid illness (AHR= 0.722, 95%CI=0.530-0.981).this means, the time needed to reach optimal glycemic control

among clients with history of comorbid illness was significantly longer compared with clients with no history of comorbid illness.

However, the rate of achieving first optimal glycemic control among clients who adhered to diabetic care had 9.7 times increment than clients who didn't adhered to diabetic management (AHR=9.723, 95%CI=6.094-15.513). (Table 6).

Table 7: Results for the final cox regression hazard model among type 1DM clients Bahir Dar city public referral hospitals,Northwest,Ethiopia,2021(n=385)

Variable	CHR(95%CI)	AHR(95% CI)	P-value
Insulin dose at	0.982(0.969-0.993)*	1.053(1.029-1.078)	< 0.001**
initiation of Rx			
Weight of the	0.978(0.965-0.992)*	0.964(0.939-0.989)	0.005**
client			
Age group in yea	rs at diagnosis		
<=5®			
>5-10	0.802(0.587-1.097)	0.926(0.619-1.384)	0.707
>10-14	0.599(0.448-0.801)*	0.324(0.192-0.546)	<0.001**
Sex of the partici	pant		
Male®			
Female	1.116(0.879-1.416)		
Resident			
Urban®			
Rural	1.010(0.790-1.292)		
Primary care give	er		
Mother alone®			
Mother and Fathe	er 0.848 (0.617-1.165)	2.092(1.397-3.132)	<0.001**
Father alone	0.824 (0.493-1.378)	1.171(0.631-2.171)	0.617
Other	0.685 (0.475-0.988)*	0.801(0.491-1.305)	0.372
Educational statu	s of children	``````````````````````````````````````	
K/not started®			
Primary school	0.746 (0.527-1.057)	0.868(0.574-1.314)	0.505
High school	0.684 (0.471-0.992)*	1.333(0.745-2.386)	0.333
Insulin regimen	×	``````````````````````````````````````	
Lent& regular®			
NPH& regular	0.840(0.631-1.118)*	0.757(.538-1.066)	0.111
NPH alone	0.704(0.511-0.970)*	1.305(0.856-1.990)	0.216
INFIT alolle	$0.704(0.311-0.970)^{\circ}$	1.303(0.830-1.990)	0.210

hospitals,Northw	vest, Ethiopia, 2021 (n=385 cont		
Carbohydrate			
counting			
NO®			
Yes	4.173(2.332-7.468)*	2.433(1.124-5.263)	0.024**
Frequency of gly	cemic control per day		
<3®			
>=3	1.904(1.409-2.574)*	1.259(0.887-1.788)	0.198
Physical exercise			
NO®			
Yes	2.574 (1.991-3.326)*	1.178(0.841-1.649)	0.341
-	behavior assessed by clinician at health car	e visit	
NO®			
Yes	0.334 (0.248-0.451)*	1.222(.805-1.853)	0.346
Adherence to dia	betic care		
NO®			
Yes	6.522(4.901-8.679)*	9.723(6.094-15.513)	<0.001**
Duration of DM			
in years			
<2®			
[2-4)	0.559(0.401-0.781)	0.736(0.509-1.063)	0.102
>=4	0.486(0.356-0.664)*	0.642(0.436-0.944)	0.024**
	acute complication		
NO®	1 501/1 021 0 457)*	1 004/ (52 1 700)	0.755
Yes Other	1.591(1.031-2.457)*	1.084(.653-1.799)	0.755
complication			
NO®			
Yes	0.746(0.456-1.221)		
History of comor			
NO®			
Yes	0.627 (0.484-0.811)*	0.722(0.530-0.981)	0.038**
1.05		0.722(0.000 0.901)	

Results for the final cox regression hazard model among type 1DM clients Bahir Dar city publ hospitals, Northwest, Ethiopia, 2021 (n=385 cont......

CHR=Crud hazard ratio, AHR=Adjusted hazard ratio, Rx=Treatment, ®=Reference group and *&** indicates statistically significant variable with bivariable& multivariable cox regression hazard model respectively.

5. DISCUSSION

In the meantime there is no adequate former similar study in pediatrics age categories, as a result the finding of this study is compared with studies conducted with exactly analogous factors that affect optimal glycemic control among type 1 diabetic children from diverse literature in different part of the country.

Time to first optimal glycemic control finding in this study is in line with another study conducted among type 1 diabetic children in united states (38) but a little bit shorter than previous study conducted in Ethiopia(9.5months) (3). This could be due to differences in age pattern, type of diabetes and comorbidity among study participants(28,31,47,49,50,55,57-60).

The finding related to overall incidence rate to achieve glycemic target in this study is less than other studies conducted in Kenya (28%),Jordan (20.9%), Saudi Arabia (39.1%), and California(33%)(39,40,50,51) but greater than a study done in Tanzania(2.6%)(26).This discrepancy can be due to differences in population characteristics, sample size, study methodology and overall health care system including resource allocation(10, 16,17,23,24,52).

In regard to predictors, the age of the participant was found to be significantly associated variables that determine time to first optimal glycemic control. The study showed that, the time needed to reach first optimal glycemic control is longer among clients of age group >10-14 years followed by the age group 6-10 years compared to clients in the age group<=5 years, indicating that for children older than 10 years, the rate of achieving optimal glycemic control decreases as age increases which is in line with study done in Tanzania ,Bulgaria, Iraq, Taiwan and Jordan (26,46,47,49,50). This can be due to the fact that As a child develops, he/she under goes a varieties of physical and life style changes(24). In addition to this, it can be also due to hormonal effect at pubertal age of the child and decline in parental supervision over different clinical aspects of diabetic care in the adolescents(46,50).

Weight of the client also significantly associated with time to first optimal glycemic control. Rate of glycemic achievement decreases by 3.6% as weight increase by one unit which means the weight of the client is 0.964 times less likely associated with optimal glycemic achievement rate.

This could be due to, weight gain may contribute to increased insulin resistance and cardio metabolic risk such as increased dyslipidemia and blood pressure(62). It is in line with another controlled study among T1DM patients which stated previously as "normal weight preschool children have better glycemic control than age matched overweight children (63,64)."It can significantly implies that, body weight status may impede achievement of glycemic targets with in the expected time in this group of patients. Therefore, having regular exercise which is non-strenuous can be encouraged. The recommendation is supported by the study conducted in United Kingdom and the authors of International society of pediatrics and adolescents diabetes (ISPAD) guide line revised since 2018 GC (6,34).

Dose of insulin at initiation of treatment increases first optimal glycemic achievement rate by 1.053 times as dose of insulin increases by one unit. This finding is supported by the study done in many countries such as India, china, Germany, Austria, and Luxembourg (66-70).

This study also showed that, primary care giver during the follow up period was significantly associated with optimal glycemic control. Especially those clients whose care giver mother and father was two times more likely associated with first optimal glycemic control as compared with clients supported by their mothers alone. The finding was supported by the study conducted in Tanzania and middle east Jordan(32,50).

In regard to adherence to diabetic care, those clients with adherence had 9.7 fold of instantaneous chance of increasing their glycemic achievement rate as compared with those clients with no adherence to wards their diabetic management. Which is in line with the study conducted in Ethiopia entitled with incidence of diabetic keto acidosis and its predictors among type one diabetic children (31).Correspondingly, those clients well adhered to Diet counseling specifically on food pyramid and non-refined carbohydrate utilization were found to have increasing their glycemic achievement rate by 2.4 folds as compared with those clients with no habit of practicing healthy diet at home and the finding is in line with the study conducted in Uganda (35, 54, 64).

Duration of diabetes was also significantly associated with time to first optimal glycemic control in this study. Those clients living with diabetes for more than or equal to four years were 35.8% times less likely to achieve optimal glycemic control as compared with clients who were living with diabetes less than two years. This could be due to age maturation with advancement of the disease following to diabetic duration as it was explained above (24, 46,50). This finding is similar with the study done in Tanzania(31) but different with study done in cameron(75).

In addition to the above factors, having comorbid illness is another important predictors that can affect time to optimal glycemic control. The rate of achieving optimal glycemic control among clients with history of comorbid illness were 27.8% times less likely as compared with clients with no comorbid illness. This is because having comorbid illness has an influence on diabetes disease progress with impairment of glucose metabolism possibly lead to deterioration of glycemic control. Comorbid illness such as infection might also cause high level of counteracting hormones which triggering an episode of hyperglycemia and could also be due to the effect of taking many drugs which can lead to drug interaction and also can decrease drug adherence which interferes with drug effectiveness. This finding is in line with the studies conducted in Saudi Arabia, Brazil and university of California, San Francisco(18,57-60).

6. STRENGTH AND LIMITATION OF THE STUDY

6.1. Strength of the study

Since the data were collected from two referral hospitals, the finding can have more power in regard to generalizability.

6.2. Limitation of the study

Since the data were collected from medical records, variables like parental socio economic factors cannot be addressed through card review which may affect the outcome of the study.

Fasting blood glucose level (FBG) measurements obtained from medical records might be subjected to measurement errors that lead to underestimated or overestimated of the result. However, effort was made to overcome this issues by taking the mean value of three month consecutive value of FBG measurements.

7. CONCLUSION AND RECOMMENDATION

7.1. Conclusion

Median survival time to first optimal glycemic control among type one diabetic children in the study area was too long. Which indicate that, clients are unprotected for both acute and chronic complication of type one diabetes mellitus. This increased risk remains higher for those clients achieving their glycemic control with in long period of time compared to those who achieved optimal glycemic control in a short period of time.

This study also showed that age, weight, dose of insulin, diet, adherence to diabetic management, primary care giver, duration of diabetes and having comorbid illness were significantly associated with time to first optimal glycemic control among type 1 diabetic children.

7.2. Recommendation

For health care worker in the hospitals

Health care provider during diabetic care monitoring at follow up clinic should focus on adherence analysis by encouraging the clients to have logbook.

Either titration of the dose or multiple daily injection of insulin at the very beginning is essential with possible close observation and precaution of hypoglycemia or if it is possible, another insulin delivery method such as continuous subcutaneous insulin infusion and insulin pump should be taken into consideration.

Children who cannot manage their diabetes effectively by their own have to get help from all family members including siblings and other family members other than their parents should be paid more attention. This is because, involving all family members in the care plan with appropriate education and knowledge until the child can reach an age where he/she can manage diabetes can significantly increase the chance of achieving optimal glycemic targets with in an intended period of time

Health care worker should also give high emphasis for clients those having comorbid illness to manage with proper integrated manner with respect to their diabetic duration.

For policy makers

Treatment guide line is recommended to prepare based on local research findings about type 1DM specifically on pediatrics age category since glycemic control was vary though age groups.

Policy maker should follow the health care services for proper implementation of developed strategies and guidelines or standards for type 1DM treatment and their follow up with active surveillance.

For future researchers

More comprehensive prospective follow up study involving factors like parental socio economic predictors and other resources relevant to manage diabetes should be carried out to provide more universal insight for possible association with time to optimal glycemic control since such factor is difficult to access only through patient medical record review.

REFERENCES

- OMS. Global Report on Diabetes. Isbn [Internet]. 2016;978:6–86. Available from: http://www.who.int/about/licensing/copyright_form/index.html%0Ahttp://www.who.int/a bout/licensing/copyright_form/index.html%0Ahttps://apps.who.int/iris/handle/10665/2048 71%0Ahttp://www.who.int/about/licensing/accessed date12/17/2020
- Care D, Suppl SS. Children and adolescents: Standards of medical care in diabetes- 2020. Diabetes Care. 2020;43(January):S163–82. https://doi.org/10.2337/dc20-S013/accessed date 12/172020
- Leulseged TW, Ayele BT. Time to optimal glycaemic control and prognostic factors among type 2 diabetes mellitus patients in public teaching hospitals in Addis Ababa, Ethiopia. PLoS One [Internet]. 2019;14(7):1–12. Available from: http://dx.doi.org/10.1371/journal.pone.0220309
- Driscoll KA, Johnson SB, Wang Y, Wright N, Deeb LC. Blood Glucose Monitoring Before and After Type 1 Diabetes Clinic Visits. J Pediatr Psychol. 2019;44(1):32–9.
- Cheneke W, Suleman S, Yemane T, Abebe G. Assessment of glycemic control using glycated hemoglobin among diabetic patients in Jimma University specialized hospital, Ethiopia. BMC Res Notes. 2016;9(1):1–10.
- DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(July):105–14. https://onlinelibrary.wiley.com/doi/full/10.1111/pedi.12737/accessed date12/17/2020
- Shah AS, Nadeau KJ. The changing face of paediatric diabetes. Diabetologia. 2020;63(4):683–91.
- Bozkaya G, Ozgu E, Karaca B. The association between estimated average glucose levels and fasting plasma glucose levels. Clinics. 2010;65(11):1077–80.
- 9. L. N, B. A, W. M, K. P. Determinants of outcome of children with type 1 diabetes in

Cameroon. Horm Res Paediatr [Internet]. 2015;84:185. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L72085 656%0Ahttp://dx.doi.org/10.1159/000437032

- Ramírez-Mendoza F, González JE, Gasca E, Camacho M, Cruz M V., Caraveo D, et al. Time in range and HbA1C after 6 months with a multidisciplinary program for children and adolescents with diabetes mellitus, real world data from Mexico City. Pediatr Diabetes. 2020;21(1):61–8.
- Musenge EM, Michelo C, Mudenda B, Manankov A. Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia. J Diabetes Res. 2016;2016.
- Adamu Y, Garba KM, YAU S, Ya'u J. Glycemic Control and its Predictors among Diabetic Patients Attending a Tertiary Hospital in Nigeria: A Retrospective Observational Study. J Biomed Anal. 2020;3(1):13–25.
- 13. Shibeshi MS, Fantahun B, Kebede T, Tilahun B. Pediatric diabetic retinopathy : experience of a tertiary hospital in Ethiopia. BMC Res Notes. 2016;1–6.
- Niba LL, Aulinger B, Mbacham WF, Parhofer KG. Predictors of glucose control in children and adolescents with type 1 diabetes: Results of a cross-sectional study in Cameroon. BMC Res Notes. 2017;10(1):1–10.
- Yazidi M, Chihaoui M, Chaker F, Rjeb O, Slimane H. Factors Predicting Glycemic Control in Type 1 Diabetic Patient. Open Med J. 2016;3(1):153–8.
- Abebe SM, Berhane Y, Worku A, Alemu S, Mesfin N. Level of sustained Glycemic control and associated factors among patients with diabetes mellitus in Ethiopia: A hospital-based cross-sectional study. Diabetes, Metab Syndr Obes Targets Ther. 2015;8:65–71.
- 17. Gebreyohannes EA, Netere AK, Belachew SA. Glycemic control among diabetic patients in Ethiopia: A systematic review and meta-analysis. PLoS One [Internet]. 2019;14(8):1– 14. Available from: http://dx.doi.org/10.1371/journal.pone.0221790
- 18. Andrade CS, Ribeiro GS, Santos CAST, Neves RCS, Moreira ED. Factors associated with

high levels of glycated haemoglobin in patients with type 1 diabetes: A multicentre study in Brazil. BMJ Open. 2017;7(12):1–10.

- Mutyambizi C, Pavlova M, Hongoro C, Groot W. Inequalities and factors associated with adherence to diabetes self-care practices amongst patients at two public hospitals in Gauteng, South Africa. BMC Endocr Disord. 2020;20(1):1–10.
- Seth A. Challenges of Achieving an Optimum Glycemic Control in Children with Type 1 Diabetes in India. Indian J Pediatr. 2020;87(7):491–2.
- 21. Kangin M, Talay MN, Tanriverdi Yilmaz S, Unal E, Demiral M, Asena M, et al. A Retrospective Analysis of Children and Adolescents With Diabetic Ketoacidosis in the Intensive Care Unit: Is It Significant that the Blood Ketone Level Becomes Negative in Diabetic Ketoacidosis? Cureus. 2020;12(10):1–8.
- Zurita Cruz JN, Dosta Martínez GE, Villasís Keever MÁ, Rivera Hernández A de J, Garrido Magaña E, Nishimura Meguro E. Pacientes pediátricos con diabetes tipo 1: crecimiento y factores asociados con su alteración. Bol Med Hosp Infant Mex. 2016;73(3):174–80.
- 23. Carneiro VL, Fraiz FC, Ferreira F de M, Pintarelli TP, Oliveira ACB, Boguszewski MC da S. The influence of glycemic control on the oral health of children and adolescents with diabetes mellitus type 1. Arch Endocrinol Metab. 2015;59(6):535–40.
- Smokovski I. Managing Diabetes in Low Income Countries. Manag Diabetes Low Income Ctries. 2021;
- 25. Tsadik AG, Atey TM, Nedi T, Fantahun B, Feyissa M. Effect of Insulin-Induced Lipodystrophy on Glycemic Control among Children and Adolescents with Diabetes in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. J Diabetes Res. 2018;2018.
- Mclarty RP, Alloyce JP, Chitema GG, Msuya LJ. Glycemic control, associated factors, acute complications of Type 1 Diabetes Mellitus in children, adolescents and young adults in Tanzania. 2020;(July):1–8.
- 27. Msanga D, Reis K, Kayange N, Bakalemwa R, Kidenya B, Hau D, et al. Diabetic microvascular complications among children and adolescents in northwestern Tanzania: A

cross-sectional study. Ann Glob Heal. 2020;86(1):1–8.

- Al-fraik NGS, Abdulrraziq SM, Najem MSM. Demographic and Clinical Characteristics of Type I Diabetes Mellitus at Tobruck Pediatric Intensive Care Unit. Middle East J Appl Sci. 2020;304–12.
- 29. Shiferaw WS, Akalu TY, Aynalem YA. Chronic Kidney Disease among Diabetes Patients in Ethiopia: A Systematic Review and Meta-Analysis. Int J Nephrol. 2020;2020.
- 30. Collin A.Ross. improved a1c readings for diabetic patients who receive feedback via text messaging. j chem inf model. 2017;53(9):1689–99.
- Zeleke H, Murugan R, Wondwossen K. Incidence and predictors of diabetic ketoacidosis among children with diabetes in west and east gojjam zone referral hospitals north west Ethiopia ,. 2019;
- 32. Noorani M, Ramaiya K, Manji K. Glycaemic control in type 1 diabetes mellitus among children and adolescents in a resource limited setting in Dar es Salaam- Tanzania. BMC Endocr Disord [Internet]. 2016;16(1):1–8. Available from: http://dx.doi.org/10.1186/s12902-016-0113-y
- 33. Hannonen R, Aunola K, Eklund K, Ahonen T. Maternal parenting styles and glycemic control in children with type 1 diabetes. Int J Environ Res Public Health. 2019;16(2).
- Taylor GS, Smith K, Capper TE, Scragg JH, Bashir A, Flatt A, et al. Postexercise glycemic control in type 1 diabetes is associated with residual b-cell function. Diabetes Care. 2020;43(10):2362–70.
- 35. Seckold R, Howley P, King BR, Bell K, Smith A, Smart CE. Dietary intake and eating patterns of young children with type 1 diabetes achieving glycemic targets. BMJ Open Diabetes Res Care. 2019;7(1).
- Al Zahrani AM, Al Shaikh A. Glycemic Control in Children and Youth With Type 1 Diabetes Mellitus in Saudi Arabia. Clin Med Insights Endocrinol Diabetes [Internet]. 2019;12. Available from: https://doi.org/10.1177/1179551418825159
- 37. Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al.

Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA - J Am Med Assoc. 2017;318(14):1358–66.

- Patton SR, Noser AE, Youngkin EM, Majidi S, Clements MA, Al PET. Early Initiation of Diabetes Devices Relates to Improved Glycemic Control in Children with Recent-Onset Type 1 Diabetes Mellitus. 2019;21(7):379–84.
- Hood KK, Ph D. Predictors of deteriorations in diabetes management and control in adolescents with type 1 diabetes. 2015;52(1):28–34.
- 40. Ngwiri T, Were F, Predieri B, Ngugi P, Iughetti L. Glycemic Control in Kenyan Children and Adolescents with Type 1 Diabetes Mellitus. Int J Endocrinol. 2015;2015.
- 41. Sarfo-Kantanka O, Sarfo FS, Ansah EO, Eghan B, Ayisi-Boateng NK, Acheamfour-Akowuah E. Secular trends in admissions and mortality rates from diabetes mellitus in the central belt of Ghana: A 31-year review. PLoS One [Internet]. 2016;11(11):1–14. Available from: http://dx.doi.org/10.1371/journal.pone.0165905
- Uleanya ND, Aniwada EC, Nwokoye IC, Ndu IK, Eke CB. Relationship between Glycemic Levels and Treatment Outcome among Critically Ill Children admitted into Emergency Room in Enugu. BMC Pediatr. 2017;17(1):1–7.
- 43. Amos M, Gladys C, Sandeni C, Alfred J, Levina M, Jedeni B, et al. Complications and Glycaemic Control of Type 1 Diabetes Mellitus amongst Children Aged 5 to 19 Years Attending Diabetic Clinic at Kamuzu Central Hospital In Malawi. Int J Diabetes Clin Res. 2020;7(1).
- 44. Teklehaimanot berhane fseha, berhe abadi kidanemariam, welearegawi gebrehiwet gebremariam. Poor glycemic control and associated factors among diabetic patients in Ethiopia; A Systemic review and meta-analysis. Poor glycemic Control Assoc factors among Diabet patients Ethiop A Syst Rev meta-analysis. 2019;19004986.
- Dumrisilp T, Supornsilchai V, Wacharasindhu S, Aroonparkmongkol S, Sahakitrungruang
 T. Factors associated with glycemic control in children and adolescents with type 1
 diabetes mellitus at a tertiary-care center in Thailand: A retrospective observational study.

Asian Biomed. 2017;11(6):443–50.

- 46. Rewers MJ, Pillay K, de Beaufort C, Craig ME, Hanas R, Acerini CL, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(SUPPL.20):102–14.
- Governorate S. Original Article Factors Affecting Glycemic Control in Type 1 Diabetes Mellitus among. 2019;8(2).
- Setoodeh A, Mostafavi F, Rabbani A, Hedayat T. Female Sex as a Risk Factor for Glycemic Control and Complications in Iranian Patients with Type One Diabetes Mellitus. 2011;21(3):373–8.
- Hsiao YT, Cheng WC, Liao WC, Lin CL, Shen TC, Chen WC, et al. Type 1 diabetes and increased risk of subsequent asthma: A nationwide population-based cohort study. Med (United States). 2015;94(36):1–6.
- Alassaf A, Odeh R, Gharaibeh L, Ibrahim S, Ajlouni K. Personal and clinical predictors of poor metabolic control in children with type 1 diabetes in Jordan. J Diabetes Res. 2019;2019:15–8.
- 51. A AlAgha M, M Majdi W, Aljefri HM, Abdelfattah Ali M, Alagha AE, Abd Elhameed IA, et al. Effect of Parents' Educational Level and Occupational Status on Child Glycemic Control. J Patient Care. 2017;03(02):2–4.
- 52. Kajee Z, Harvey J, Zöllner EW. The impact of a diabetes care team on the glycaemic control of paediatric and adolescent patients with type 1 diabetes mellitus at tygerberg children's hospital. SAJCH South African J Child Heal. 2019;13(1):12–6.
- 53. Haynes A, Hermann JM, Clapin H, Hofer SE, Karges B, Jones TW, et al. Decreasing trends in mean HbA1c are not associated with increasing rates of severe hypoglycemia in children: A longitudinal analysis of two contemporary population-based pediatric type 1 diabetes registries from Australia and Germany/Austria between 1995. Diabetes Care. 2019;42(9):1630–6.
- Ndahura NB, Munga J, Kimiywe J, Mupere E. Caregivers 'Nutrition Knowledge and Dietary Intake of Type 1 Diabetic Children Aged 3 – 14 Years in Uganda. 2021;127–37.

- 55. Sildorf SM, Breinegaard N, Lindkvist EB, Tolstrup JS, Boisen KA, Teilmann GK, et al. Poor metabolic control in children and adolescents with type 1 diabetes and psychiatric comorbidity. Diabetes Care. 2018;41(11):2289–96.
- 56. Schoenaker DAJM, Simon D, Chaturvedi N, Fuller JH, Soedamah-Muthu SS. Glycemic control and all-cause mortality risk in type 1 diabetes patients: The EURODIAB prospective complications study. J Clin Endocrinol Metab. 2014;99(3):800–7.
- Krzewska A, Ben-Skowronek I. Effect of Associated Autoimmune Diseases on Type 1 Diabetes Mellitus Incidence and Metabolic Control in Children and Adolescents. Biomed Res Int. 2016;2016.
- 58. Al-Agha AE, Alafif M, Abd-Elhameed IA. Glycemic control, Complications, and associated autoimmune diseases in children and adolescents with type 1 diabetes in Jeddah, Saudi Arabia. Saudi Med J. 2015;36(1):26–31.
- Calliari LE, Almeida FJ, Noronha RM. Infections in children with diabetes. J Pediatr (Rio J). 2020;96:39–46.
- 60. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 Diabetes in Children and Adolescents : A Position Statement by the American Diabetes Association. 2018;41(September):2026–44. https://care.diabetesjournals.org/content/41/9/2026.article-info/accessed date 12/17/2020
- Mbbs SAI, Edin F, Mbbs GA, Bajaj HS, Mb SR. Targets for Glycemic Control Diabetes Canada Clinical Practice Guidelines Expert Committee. 2018;42:42–6. https://guidelines.diabetes.ca/cpg/chapter34/accessed date1/162021
- Jaja TC, Yarhere IE. Dyslipidaemia in Nigerian Children and Adolescents with Diabetes Mellitus: Prevalence and Associated Risk Factors. Int J Diabetes Metab. 2019;25(1– 2):45–51.
- 63. T.R. Nansel, PhD1, L.M. Lipsky, PhD1, and R.J. Iannotti P. Cross-sectional and longitudinal relationships of body mass index with glycemic control in children and adolescents with type 1 diabetes mellitus. 2014;100(1):126–32.
- 64. Kerkeni L, Ruano P, Delgado LL, Picco S, Villegas L, Tonelli F, et al. Nutritional

Management in Type 1 Diabetes Mellitus. Intech [Internet]. 2016;(tourism):13. Available from: https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics

- 65. Teni DA, Enquoselassie F, Atsmegiorgis C. Survival analysis of diabetes mellitus patients using parametric , non-parametric and semi-parametric approaches : Addis Ababa , Ethiopia. Ethiop e-Journal Res Innov Foresight. 2015;7(1):20–39.
- 66. Wangnoo SK. Initiating insulin therapy in children and adolescents with type 1 diabetes mellitus. Indian J Endocrinol Metab. 2015;19(7):S68–70.
- Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes. 2019;10(1):1–15.
- 68. Thabit H, Prabhu JN, Mubita W, Fullwood C, Azmi S, Urwin A, et al. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. Diabetes Care. 2020;43(10):2537–43.
- Maiorino MI, Signoriello S, Maio A, Chiodini P, Bellastella G, Scappaticcio L, et al. Effects of continuous glucose monitoringonmetricsofglycemic control in diabetes: A Systematic Review with Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020;43(5):1146–56.
- Klatman EL, Ogle GD. Access to insulin delivery devices and glycated haemoglobin in lower-income countries. World J Diabetes. 2020;11(8):358–69.
- DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, et al.
 Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018;19(7):1271–5.
- Zuberi Z, Sauli E, Cun L, Deng J, Li WJ, He XL, et al. Insulin-delivery methods for children and adolescents with type 1 diabetes. Ther Adv Endocrinol Metab [Internet]. 2020;11:1–13. Available from: https://doi.org/10.1177/2042018820906016
- 73. Djonou C, Tankeu AT, Dehayem MY, Tcheutchoua DN, Mbanya JC, Sobngwi E.

Glycemic control and correlates in a group of sub Saharan type 1 diabetes adolescents. BMC Res Notes [Internet]. 2019;1–5. Available from: https://doi.org/10.1186/s13104-019-4054-1

- Nuche-Berenguer B, Kupfer LE. Erratum to 'Readiness of Sub-Saharan Africa Healthcare Systems for the New Pandemic, Diabetes: A Systematic Review'. J Diabetes Res. 2018;2018:3419290.
- 75. Djonou C, Tankeu AT, Dehayem MY, Tcheutchoua DN, Mbanya JC, Sobngwi E. Glycemic control and correlates in a group of sub Saharan type 1 diabetes adolescents 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Res Notes [Internet]. 2019;12(1):1–5. Available from: https://doi.org/10.1186/s13104-019-4054-1
- 76. Taha Z, Eltoum Z, Washi S. Predictors of glucose control in children and adolescents with type 1 diabetes: Results of a cross-sectional study in Khartoum, Sudan. Open Access Maced J Med Sci. 2018;6(11):2035–9.
- Ganu D. Increasing Incidence and Prevalence of Type 1 Diabetes in Children Under 20 Years of Age between 1999-2019 in Sub-Saharan Africa : A Systematic Review. 2020;3(1):1–8.
- Home P, Haddad J, Latif ZA, Soewondo P, Benabbas Y, Litwak L, et al. Comparison of national/regional diabetes guidelines for the management of blood glucose control in nonwestern countries. Diabetes Ther. 2013;4(1):91–102.
- 79. Hitt JM. Hemoglobin A1C and the Diagnosis of Diabetes and Prediabetes in Children and Adolescents. Hemoglobin A1c Diagnosis Diabetes Prediabetes Child Adolesc. 2014;67 p.
- MOH. Guidelines on Clinical and Programmatic Management of Major Non Communicable Diseases. 2016;220. https://extranet.who.int/ncdccs/Data/ETH_D1_National%20NCD%20Guideline/accessed date 12/17/2020

ANNEXES

ANNEX-I: INFORMATION SHEET FOR STAFFS WORKING ON PATIENT'S CARD ROOM AT BAIR DAR CITY PUBLIC REFERRAL HOSPITALS, 2021

I am MSC student from Bahir Dar University College of medicine and health science, department of pediatrics and child health nursing. I want to kindly ask you to observe the following questions from patient registry/follow up card. The main aim of this data collection is to estimate time to first optimal glycemic control and identify its predictors among type one diabetic children. Confidentiality of the information is well secured. Because of this, it is not requested to write clients name. The finding of this credible information uses not only for accomplishment of this study, but also results obtained from this study will potentially help health care managers and professionals to develop a new strategy for the prevention and management of both acute and chronic complication of DM in children and it will give a new insight for a national program of research team for further interventional studies in the country.

ANNEX-II: CHECK LIST TO COLLECT RELEVANT INFORMATION TO MEASURE ASSOCIATION BETWEEN TIME AND OPTIMAL GLYCEMIC CONTROL AMONG DIABETIC CHILDREN IN BAHIR DAR CITY REFERRAL HOSPITALS, 2021 (Adopted from (3,15,36,40,50))

Part I	Part I: socio demographic characteristics					
S.No.	Questions	Responses	Skip			
1.	Age at diagnosis					
2.	current age (years)					
3.	Sex	1. male				
		2. female				
4.	Residence	1. urban				
		2. rural				
5.	Hospital in which the data obtained	1. Felege Hiwot				
		2. Tibebe Ghion				
6.	Educational status of the children	1. KG/not started				
		2. Primary school (1-				
		8)				
		3. Grade 9 -12				
		4. other(specify)				
7.	Primary care giver	1.Mother alone				

		2.Mothe&Father
		3.Father alone
		4.Other(specify)
	Personal and clinical related variables	
8.	BMI and MUAC in the latest clinic visit	Wtkg
		Htcm
		MUACcm
9.	Family history of diabetes	0.NO
		1.Yes
10.	Duration of diabetes (years)	
11	Number of division into the location of fully	
11.	Number of clinic visits during the last year of follow	
12.	up First insulin regimen	
12.	i iist iiisuilli regilieli	
13.	Current insulin regimen	
14.	Number of insulin injection per day	
15.	dose of First insulin	
13.		
16.	Current insulin dose	
17.	Frequency of daily glucose control	
18.	Carbohydrate count	0.NO
		1.Yes
19.	parental/self-reported physical activity	0.NO
		1.Yes
20.	Presence of noncompliance behaviors assessed	0 NO
	by the clinician at the time of health care visit	1 Yes
	: diabetes related complication	
21.	History of diabetes related complication	0.NO
		1.Yes
22.	Diabetes related acute complication	0.NO
		1.Yes
23.	Diabetic keto acidosis	0.NO
24	humo aluceuria	1.Yes
24.	hypoglycemia	0.NO 1.Yes
25.	Diabetes nephropathy	0.NO
23.		1.Yes
26.	Diabetes neuropathy	0.NO
26.	Diabetes neuropathy	U.NU

					1.Yes		
27.	Diabet	es retinopathy	7		0.NO		
					1.Yes		
28.	Other of	complications			0.NO		
		I			1.Yes		
29.	More t	han one comp	olication		0.NO		
		1			1.Yes		
30.	Diabet	es related hos	pitalization		0.NO		
					1.Yes		
Part IV	/: comorbi	idity related Va	riables				
31.	History	y of co-morbio	d illness		0.NO		
	-				1.Yes		
32.	Autoin	nmune disease	e(Celiac, graves	s' disease etc)	0.NO		
				,	1.Yes		
33.	Hypert	ension			0.NO		
	• •				1.Yes		
34.	Cardio	vascular disea	ise		0.NO		
					1.Yes		
35.	dyslipi	demia			0.NO		
					1.Yes		
36.	Other of	co-morbid illn	ess(TB,HIV, and	nemia, and	0.NO		
	other in	nfections)			1.Yes		
37.	More t	han one co-m	orbid illness		0.NO		
					1.Yes		
Part V	: Glycemi	c value with re	spect to time				
Time		2016	2017	2018	2019	2020	
1							
2							
3							
4							
5							
6							
7							

343823650 0.8968 0.0161 $0.86040.924$ 452963212 0.7979 0.0218 $0.75100.836$ 562523016 0.6998 0.0255 $0.64670.746$ 67206238 0.6201 0.0274 $0.56380.671$ 78175163 0.5629 0.0284 $0.50530.616$ 89156182 0.4975 0.0290 $0.43950.552$ 910136170 0.4353 0.0290 $0.37790.492$ 101111980 0.4061 0.0289 $0.34930.462$ 1112111162 0.3470 0.0282 $0.29220.402$ 121393132 0.2980 0.0273 $0.24560.352$ 13147863 0.2746 0.0268 $0.22350.328$ 141569120 0.2268 0.0254 $0.17900.278$ 151657100 0.1870 0.0239 $0.14280.236$ 16174770 0.1592 0.0225 $0.11800.206$ 17184070 0.0947 0.0183 $0.06280.134$ 20212320 0.0864 0.0176 $0.05600.124$ 22232101 0.0820 0.0173 $0.05240.114$ 2425	Interval	Total	Deaths	Lost	Survival	Std.Error	[95% Conf. Int.]
4 5 296 32 12 0.7979 0.0218 0.7510 0.836 5 6 252 30 16 0.6998 0.0255 0.6467 0.746 6 7 206 23 8 0.6201 0.0274 0.5638 0.671 7 8 175 16 3 0.5629 0.0284 0.5053 0.616 8 9 156 18 2 0.4975 0.0290 0.4395 0.552 9 10 136 17 0 0.4353 0.0290 0.3779 0.491 10 11 119 8 0 0.4061 0.0289 0.3493 0.462 11 12 111 16 2 0.3470 0.0282 0.2922 0.402 12 13 93 13 2 0.2980 0.0273 0.2456 0.352 13 14 78 6 3 0.2746 0.0268 0.2235 0.328 14 15 69 12 0 0.2268 0.0254 0.1790 0.278 15 16 57 10 0 0.1870 0.0239 0.1428 0.235 16 17 47 7 0 0.1592 0.0225 0.1180 0.226 17 18 40 7 0 0.1313 0.0229 0.938 0.172 18 19 33 5 1 0.0864 <td>2 3</td> <td>385</td> <td>1</td> <td>2</td> <td>0.9974</td> <td>0.0026</td> <td>0.9817 0.9996</td>	2 3	385	1	2	0.9974	0.0026	0.9817 0.9996
562523016 0.6998 0.0255 0.6467 0.746 67206238 0.6201 0.0274 0.5638 0.671 78175163 0.5629 0.0284 0.5053 0.616 89156182 0.4975 0.0290 0.4395 0.552 910136170 0.4353 0.0290 0.3779 0.491 101111980 0.4061 0.0289 0.3493 0.462 1112111162 0.3470 0.0282 0.2922 0.402 121393132 0.2980 0.0273 0.2456 0.352 13147863 0.2746 0.0268 0.2235 0.328 141569120 0.2268 0.0254 0.1790 0.278 151657100 0.1870 0.0239 0.1428 0.235 16174770 0.1592 0.0225 0.1180 0.202 17184070 0.1313 0.0209 0.0938 0.172 18193351 0.1111 0.0176 0.0560 0.124 22232101 0.0864 0.0176 0.0560 0.124 23242011 0.0864 0.0176 <th< td=""><td>3 4</td><td>382</td><td>36</td><td>50</td><td>0.8968</td><td>0.0161</td><td>0.8604 0.9241</td></th<>	3 4	382	36	50	0.8968	0.0161	0.8604 0.9241
67206238 0.6201 0.0274 0.5638 0.671 78175163 0.5629 0.0284 0.5053 0.616 89156182 0.4975 0.0290 0.4395 0.555 910136170 0.4353 0.0290 0.3779 0.491 101111980 0.4061 0.0289 0.3493 0.462 1112111162 0.3470 0.0282 0.2922 0.402 121393132 0.2980 0.0273 0.2456 0.352 13147863 0.2746 0.0268 0.2235 0.328 141569120 0.2268 0.0254 0.1790 0.278 151657100 0.1870 0.0239 0.1428 0.236 16174770 0.1592 0.0225 0.1180 0.202 17184070 0.1313 0.0209 0.0938 0.172 18193351 0.1111 0.0195 0.0560 0.124 22232101 0.0864 0.0176 0.0560 0.124 23242011 0.0820 0.0131 0.0228 0.0377 0.992 26271431 0.0496	4 5	296	32	12	0.7979	0.0218	0.7510 0.8369
78175163 0.5629 0.0284 0.5053 0.616 89156182 0.4975 0.0290 0.4395 0.553 910136170 0.4353 0.0290 0.3779 0.491 101111980 0.4061 0.0289 0.3493 0.462 1112111162 0.3470 0.0282 0.2922 0.402 121393132 0.2980 0.0273 0.2456 0.352 13147863 0.2746 0.0268 0.2235 0.328 141569120 0.2268 0.0254 0.1790 0.788 151657100 0.1870 0.0239 0.1428 0.235 16174770 0.1592 0.0225 0.1180 0.203 17184070 0.1313 0.0209 0.0938 0.172 18193351 0.1111 0.0176 0.0560 0.124 20212320 0.0864 0.0176 0.0560 0.124 22232101 0.0864 0.0176 0.0560 0.124 24251840 0.0638 0.0156 0.0377 0.092 26271431 0.0496 0.0141	5 6	252	30	16	0.6998	0.0255	0.6467 0.7465
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	6 7	206	23	8	0.6201	0.0274	0.5638 0.6713
910136170 0.4353 0.0290 $0.3779 0.491$ 101111980 0.4061 0.0289 $0.3493 0.462$ 1112111162 0.3470 0.0282 $0.2922 0.402$ 121393132 0.2980 0.0273 $0.2456 0.352$ 13147863 0.2746 0.0268 $0.2235 0.328$ 141569120 0.2268 0.0254 $0.1790 0.278$ 151657100 0.1870 0.0239 $0.1428 0.236$ 16174770 0.1592 0.0225 $0.1180 0.205$ 17184070 0.1313 0.0209 $0.0938 0.175$ 18193351 0.1111 0.0195 $0.0765 0.152$ 19202740 0.0947 0.0183 $0.0628 0.124$ 22232101 0.0864 0.0176 $0.0560 0.124$ 23242011 0.0864 0.0176 $0.0560 0.124$ 24251840 0.0638 0.0156 $0.0377 0.099$ 26271431 0.0496 0.0141 $0.0268 0.082$ 27281001 0.0496 0.0141 $0.0268 0.082$ 2829911 0.0250 0.0113 $0.0092 0.055$	7 8	175	16	3	0.5629	0.0284	0.5053 0.6164
10 11 119 8 0 0.4061 0.0289 0.3493 0.462 11 12 111 16 2 0.3470 0.0282 0.2922 0.402 12 13 93 13 2 0.2980 0.0273 0.2456 0.352 13 14 78 6 3 0.2746 0.0268 0.2235 0.328 14 15 69 12 0 0.2268 0.0254 0.1790 0.278 15 16 57 10 0 0.1870 0.0239 0.1428 0.236 16 17 47 7 0 0.1592 0.0225 0.1180 0.205 17 18 40 7 0 0.1313 0.0209 0.0938 0.175 18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0250 <	8 9	156	18	2	0.4975	0.0290	0.4395 0.5528
1112111162 0.3470 0.0282 0.2922 0.402 121393132 0.2980 0.0273 0.2456 0.525 13147863 0.2746 0.0268 0.2235 0.328 141569120 0.2268 0.0254 0.1790 0.278 151657100 0.1870 0.0239 0.1428 0.236 16174770 0.1592 0.0225 0.1180 0.205 17184070 0.1313 0.0209 0.0938 0.175 18193351 0.1111 0.0195 0.0765 0.152 19202740 0.0947 0.0183 0.0628 0.124 20212320 0.0864 0.0176 0.0560 0.124 23242011 0.0820 0.0173 0.0524 0.1124 24251840 0.0638 0.0156 0.0377 0.092 26271431 0.0496 0.0141 0.0268 0.082 2829911 0.0438 0.0136 0.0223 0.0765 3031720 0.0313 0.0123 0.0132 0.0628 3536401 0.0250 0.0113 0	9 10	136	17	0	0.4353	0.0290	0.3779 0.4913
12 13 93 13 2 0.2980 0.0273 0.2456 0.352 13 14 78 6 3 0.2746 0.0268 0.2235 0.328 14 15 69 12 0 0.2268 0.0254 0.1790 0.278 15 16 57 10 0 0.1870 0.0239 0.1428 0.236 16 17 47 7 0 0.1592 0.0225 0.1180 0.203 16 17 47 7 0 0.1592 0.0225 0.1180 0.203 17 18 40 7 0 0.1313 0.0209 0.0938 0.175 18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.124 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0820 0.0173 0.0524 0.124 23 24 20 1 1 0.0496 0.0141 0.0268 0.082 24 25 18 4 0 0.0496 0.0141 0.0268 0.082 24 25 18 4 0 0.0313 0.0123 0.0132 0.062 27 28 10 0 1 0.0496	10 11	119	8	0	0.4061	0.0289	0.3493 0.4620
13147863 0.2746 0.0268 0.2235 0.328 141569120 0.2268 0.0254 0.1790 0.278 151657100 0.1870 0.0239 0.1428 0.236 16174770 0.1592 0.0225 0.1180 0.205 17184070 0.1313 0.0209 0.0938 0.175 18193351 0.1111 0.0195 0.0765 0.152 19202740 0.0947 0.0183 0.0628 0.124 20212320 0.0864 0.0176 0.0560 0.124 22232101 0.0864 0.0176 0.0560 0.124 23242011 0.0820 0.0173 0.0524 0.118 24251840 0.0638 0.0156 0.0377 0.092 26271431 0.0496 0.0141 0.0268 0.082 2829911 0.0438 0.0136 0.0223 0.076 3031720 0.0313 0.0123 0.0132 0.0092 0.055 3536401 0.0250 0.0113 0.0092 0.055	11 12	111	16	2	0.3470	0.0282	0.2922 0.4023
14 15 69 12 0 0.2268 0.0254 0.1790 0.278 15 16 57 10 0 0.1870 0.0239 0.1428 0.236 16 17 47 7 0 0.1592 0.0225 0.1180 0.205 17 18 40 7 0 0.1313 0.0209 0.0938 0.175 18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.134 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.116 24 25 18 4 0 0.0638 0.0156 0.0377 0.092 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.0635 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	12 13	93	13	2	0.2980	0.0273	0.2456 0.3521
15 16 57 10 0 0.1870 0.0239 0.1428 0.236 16 17 47 7 0 0.1592 0.0225 0.1180 0.205 17 18 40 7 0 0.1313 0.0209 0.0938 0.175 18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.1342 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.124 24 25 18 4 0 0.0638 0.0156 0.0377 0.092 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0092 0.055 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0	13 14	78	6	3	0.2746	0.0268	0.2235 0.3280
16 17 47 7 0 0.1592 0.0225 0.1180 0.205 17 18 40 7 0 0.1313 0.0209 0.0938 0.175 18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.134 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0864 0.0176 0.0560 0.124 24 25 18 4 0 0.0638 0.0176 0.0377 0.092 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.0623 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	14 15	69	12	0	0.2268	0.0254	0.1790 0.2782
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	15 16	57	10	0	0.1870	0.0239	0.1428 0.2360
18 19 33 5 1 0.1111 0.0195 0.0765 0.152 19 20 27 4 0 0.0947 0.0183 0.0628 0.134 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.114 24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.82 27 28 10 0 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1	16 17	47	7	0	0.1592	0.0225	0.1180 0.2059
19 20 27 4 0 0.0947 0.0183 0.0628 0.134 20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.119 24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.82 27 28 10 0 1 0.0496 0.0141 0.0268 0.82 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1	17 18	40	7	0	0.1313	0.0209	0.0938 0.1753
20 21 23 2 0 0.0864 0.0176 0.0560 0.124 22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.119 24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	18 19	33	5	1	0.1111	0.0195	0.0765 0.1529
22 23 21 0 1 0.0864 0.0176 0.0560 0.124 23 24 20 1 1 0.0820 0.0173 0.0524 0.119 24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0496 0.0141 0.0268 0.082 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	19 20	27	4	0	0.0947	0.0183	0.0628 0.1343
23 24 20 1 1 0.0820 0.0173 0.0524 0.119 24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0496 0.0141 0.0268 0.082 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	20 21	23	2	0	0.0864	0.0176	0.0560 0.1249
24 25 18 4 0 0.0638 0.0156 0.0377 0.099 26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0496 0.0141 0.0268 0.082 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	22 23	21	0	1	0.0864	0.0176	0.0560 0.1249
26 27 14 3 1 0.0496 0.0141 0.0268 0.082 27 28 10 0 1 0.0496 0.0141 0.0268 0.082 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	23 24	20	1	1	0.0820	0.0173	0.0524 0.1199
27 28 10 0 1 0.0496 0.0141 0.0268 0.082 28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	24 25	18	4	0	0.0638	0.0156	0.0377 0.0991
28 29 9 1 1 0.0438 0.0136 0.0223 0.076 30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	26 27	14	3	1	0.0496	0.0141	0.0268 0.0826
30 31 7 2 0 0.0313 0.0123 0.0132 0.062 33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	27 28	10	0	1	0.0496	0.0141	0.0268 0.0826
33 34 5 1 0 0.0250 0.0113 0.0092 0.055 35 36 4 0 1 0.0250 0.0113 0.0092 0.055	28 29	9	1	1	0.0438	0.0136	0.0223 0.0762
35 36 4 0 1 0.0250 0.0113 0.0092 0.055	30 31	7	2	0	0.0313	0.0123	0.0132 0.0623
	33 34	5	1	0	0.0250	0.0113	0.0092 0.0550
	35 36	4	0	1	0.0250	0.0113	0.0092 0.0550
	36 37	3	1	2	0.0125	0.0105	0.0017 0.0493

ANNEX-III: LIFE TABLE TO ESTIMATE CUMULATIVE SURVIVAL PROBABILITY AFTER DIAGNOSIS

ANNEX: IV TEST OF INTERACTION BY MULTICOLLINEARITY

. vif

Variable	VIF	1/VIF
currenid	6.19	0.161523
dosi	5.47	0.182835
agegroupd	4.63	0.216154
wt	4.33	0.230861
adhernce	4.15	0.241222
morethal	4.14	0.241548
curentageg	4.08	0.244930
sammam	3.87	0.258372
frquofgg	3.63	0.275159
primarc	3.24	0.308482
othercbd	2.97	0.336315
moreth1c	2.92	0.342784
coplianc	2.85	0.350985
BMIcat	2.84	0.351538
hypog	2.84	0.352237
hxcdty	2.70	0.370860
dka	2.62	0.381242
durDMcat	2.57	0.389033
freqdglcat	2.47	0.404224
hospital	2.47	0.404664
diabetes	2.21	0.453310
firir	2.17	0.461761
otherc	2.12	0.471449
ccdm	2.08	0.481602
cvsd	2.07	0.483513
educatio	2.06	0.486103
exercis	1.95	0.513262
cap	1.89	0.528226
urti	1.84	0.544794
stunting	1.83	0.545131
residenc	1.83	0.547942
currenti	1.81	0.553894
place	1.78	0.562501
uti	1.74	0.573998
htn	1.70	0.589494
sex	1.68	0.594985
age	1.65	0.607017
diec	1.63	0.615089
hep	1.62	0.618014
autoimdi	1.59	0.629182
om	1.58	0.631063
malaria	1.56	0.642475
fungali	1.54	0.648018
tb	1.52	0.657317
mengitis	1.44	0.695909
noclvisi	1.42	0.702323
familyhx	1.31	0.761318
Mean VIF	2.52	